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ABSTRACT 
Viruses infect a vast majority of the other species on the planet and rarely leave the 
host undamaged. Most human viruses need to infect an individual to replicate and 
disseminate, and must contend with the full force of the human immune system. On 
the host side, immune cells must withstand virus infection, impairment of function 
and possible death, to recruit other immune cells, train them against the specific 
weaknesses of the adversary, muster a host, eliminate the threat, and leave behind 
a legacy of sentinels who maintain immune memory. Host-pathogen interactions are, 
in many ways, like warfare. In this thesis, we describe an important early aspect of 
the human immune response to two re-emerging viruses of global importance– 
influenza viruses and hantaviruses. Both influenza viruses and hantaviruses are 
pathogens which enter through the respiratory route but cause vastly different 
diseases. A strong, proinflammatory innate response is mounted against influenza 
viruses, but clearance of virus is carried out by antigen-specific adaptive responses. 
On the other hand, hantavirus disease is only recognizable once the host immune 
response has injured the vasculature and starting the cascade of hemorrhagic 
events associated with the disease. In both instances, the adaptive responses rely 
on efficient programming and specification by innate immune cells including 
monocytes and dendritic cells (DCs). In this thesis, we investigated the different roles 
played by monocytes and DCs during human influenza A virus (IAV) and Puumala 
orthohantavirus infections.    
We first investigated the functional differences between human plasmacytoid DCs 
(PDCs) from different tissues in the context of IAV infection. We found that PDCs in 
blood are more potent producers of the antiviral mediator, IFN, than tonsil-resident 
PDCs. Next, we studied the distribution and function of monocytes and DCs in 
circulation and in the upper respiratory tract during acute influenza disease. We 
observed that IAV infection resulted in expansion of specialized inflammatory 
monocytes in circulation which cause inflammation via TNF. Additionally, 
monocytes and DCs were recruited to the nasopharynx, where the virus is typically 
located and we found significant evidence of local TNF and inflammation. To 
assess whether monocyte and DC redistribution is also provoked by hantavirus 
infections, we studied patients suffering from hemorrhagic fever with renal syndrome 
(HFRS) due to Puumala orthohantavirus. We report a dramatic loss of monocytes 
and DCs in peripheral circulation during acute HFRS and indications of migratory 
chemokine signaling. And finally, we assessed the influence of disease severity on 
monocyte redistribution in acute HFRS. We found that severe HFRS is characterized 
by depletion of nonclassical monocytes from circulation and impairment of myeloid 
cell ability to respond to additional TLR stimuli. The findings in this thesis indicate 
tissue- and pathogen-specific differences in inflammatory behavior of human 
monocytes and DCs.        
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1 INTRODUCTION 
 
The human immune system functions as the body’s physiological defense system to 
maintain health and homeostasis. Immune cells are constantly vigilant of the threats 
from foreign antigens and pathogens that come into contact with the body, both 
externally and internally. Immune cells, which circulate in blood and line the various 
mucosal surfaces, recognize and respond to pathogens, educate and establish 
immune memory, facilitate recall responses in the event of re-exposure, and 
importantly, discriminate between self and non-self antigens. The human immune 
system is comprised of many integral components- a wide range of immune cells, 
receptors, ligands and effector molecules, and importantly, the signaling pathways 
they use to communicate. Every branch of the immune system has distinct functions, 
all individually programmed to act synergistically to exert potent protective effects.  
Of the different pathogens that infect humans to cause disease, viruses have 
remained perhaps the most enigmatic. Viruses are inert infectious particles 
comprising proteins, nucleic acids and lipids which enter a host cell (prokaryotic or 
eukaryotic) and hijack cellular machinery to self-propagate. Speculations of the 
existence of viruses, and of their contribution to human disease can be traced back 
to Louis Pasteur who suspected that rabies was caused by a pathogen smaller than 
bacilli [1]. Subsequently, “filterable” pathogenic agents were discovered which were 
then named viruses. The human influenza virus, a pathogen causing millions of 
infections annually, was isolated only in 1933 [2], over a decade after the 1918 
pandemic H1N1 influenza that killed 50 million people [3]. Several decades later, the 
mechanisms by which the 1918 influenza strain proceeded to cause a global 
pandemic were starting to be understood [4]. Key among them, aberrantly strong 
immune responses were observed in individuals who died from infection including 
severe pulmonary pathology resulting in epithelial damage, pulmonary edema and 
hemorrhage [5, 6]. Tracing the origin and mechanism of abnormal responses was 
aided by a better understanding of immune cell biology and function at steady state, 
that was acquired over this period of time.   
During this time, following the 1908 Nobel Prize in Physiology and Medicine, 
awarded to Ilya Metchnikoff and Paul Ehrlich, “in recognition of their work on 
immunity”, the field of immunology evolved from its nascent stages and became a 
cornerstone of biological research. The emergence of the field of immunology dates 
back to seminal contributions from Edward Jenner (1796, small pox vaccination); 
Ernst Haeckel (1862, phagocytosis); Paul Ehrlich (1877, hematological staining and 
mast cell discovery); Robert Koch, Louis Pasteur and Emile Roux (1876-78, germ 
theory of disease, attenuation of virulence and acquired immunity); and Ilya 
Metchnikoff (1882, phagocytosis and the cellular basis of immunity) [7]. Rapidly, the 
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complexity of the cells and molecules of the immune system started to be described. 
Of note, the distinction between innate and adaptive immune responses was made 
following the discovery of dependency of the “lymphoid” cells on “macrophage” 
function [8]. The innate immune system, in particular the mononuclear phagocytes 
(MNPs: coined by Ralph van Furth) were then identified as the sentinels of the 
immune system [9]. Comprised of monocytes, dendritic cells (DCs) and 
macrophages, MNPs are capable of surveillance for, uptake of, processing and 
presentation of foreign antigens, to initiate and orchestrate adaptive responses [10].   
In the context of a virus infection, specific and efficient humoral and cytotoxic 
immune responses are essential to clear the infection, minimize host damage and 
establish immune memory. Each of the MNP subsets have distinct functions during 
homeostasis and during viral infection. MNPs also possess the ability to migrate to 
the site of inflammation [11], and to acquire functions of other subsets [12]. However, 
MNPs are themselves susceptible to viral infection [13], sometimes facilitating the 
spread of the virus while compromising MNP functions [14]. Over the course of viral 
disease and during resolution of infection, MNPs reflect the onset of inflammation, 
instruction of the adaptive response, control of infection by effector cells, subsidence 
of inflammation and return to steady state. So, mapping the individual contributions 
of each MNP subset, across tissues, over time and in relation to one another is an 
ongoing task. Detailed in vitro studies and elegant animal models have made 
meaningful contributions to this field. Human immunology is following, not too far 
behind.  
In this thesis, we attempted to expand our current understanding of MNP function 
during viral infection by comparing immune responses of human MNPs found in 
blood and at the site of Influenza A virus (IAV) infection (Papers I and II). 
Additionally, we investigated MNP behavior during hemorrhagic fever with renal 
syndrome (HFRS) due to Puumala virus infections by detailed, longitudinal and 
functional characterization in patients (Papers III and IV). Taken together, the 
findings from this thesis improve our knowledge of monocyte and DC distribution and 
function in human influenza virus and hantavirus infections.  
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2 AIMS OF THESIS 
The general aims of the thesis were to describe the role of human monocytes and 
DCs, from blood and the tissues of interest during infection in vitro and in vivo. We 
aimed to study how they redistribute, mature, cause inflammation, provide antiviral 
protection, shape adaptive responses and thereby dictate disease severity in viral 
infection. The specific aims were as follows:   
 
• To compare how human blood and lymphoid tissue-resident plasmacytoid 
DCs respond to IAV exposure in vitro (Paper I). 
 
• To study how seasonal human IAV infection influences monocyte and DC 
redistribution between blood and the nasopharynx (Paper II).  
 
• To study how DCs and monocytes are redistributed in blood and airways 
during hemorrhagic fever with renal syndrome (HFRS) (Paper III).  
 
• To assess how severity of HFRS influences the kinetics of monocyte 
redistribution and activation during HFRS (Paper IV). 
   
3 RESPIRATORY VIRUSES 
Respiratory infections, especially of the lower tract, contribute significantly to global 
disease burden and cause an estimated 2.37 million deaths annually [15], with acute 
respiratory virus infections being the second largest contributor to this number. 
Mortality is especially high in children under the age of 5 years and adults over the 
age of 70 years. Respiratory virus infections are associated with increased risk of 
hospitalization and premature mortality. For children, survival of respiratory viral 
infection may be associated with increased risk of chronic respiratory diseases like 
asthma and chronic obstructive pulmonary disease (COPD) during adulthood [16]. 
Many respiratory viruses pose a global threat, on account of high mutation rate, 
pandemic potential, rapid transmission, lack of effective vaccines and antivirals, 
partial vaccination coverage and very often, lack of accurate numbers from areas of 
high risk and incidence [17]. The human influenza viruses are a perfect example 
fitting all the above parameters, primarily causing upper respiratory tract infections 
[18]. Of the millions of cases of seasonal influenza infections, only a small proportion 
of patients have lower airway involvement, often in the form of primary viral or 
secondary bacterial pneumonia [19]. Hantaviruses, on the other hand, are also 
transmitted via the respiratory route. But in addition to causing (lower) respiratory 
tract symptoms, hantaviruses can have broader effects on the circulatory system 
and the kidneys [20]. This thesis includes papers on both influenza and hantavirus 
infections in humans.  
3.1 INFLUENZA A VIRUS (IAV) 
Influenza, or the “flu”, caused primarily by Influenza A virus (IAV), results in over 
650,000 deaths annually [21]. This number is significantly elevated during a 
pandemic like the Spanish flu (1918-19), which led to about 50 million deaths. Due to 
the global disease burden, and the pandemic potential of IAV; influenza infections 
are carefully monitored by the WHO Global Influenza Surveillance and Response 
System (GISRS), CDC (USA) and ECDC (Europe). In Sweden, 
Folkhälsomyndigheten (Public Health Agency of Sweden) carries out sentinel 
surveillance of influenza. 
  
Figure 1. The Influenza disease burden. 
The clinical manifestation of influenza 
disease spans a broad range. The virus 
remains transmissible at every stage. The 
CDC estimates that since 2010, influenza 
has caused between 9.3 and 49 million 
cases in the US alone. Around 10% of 
these cases were hospitalized and a little 
under 1% succumbed to influenza.    
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During a typical influenza season, only a fraction of the population exposed to the 
virus develop symptomatic disease. The manifestation can range from mild, 
subclinical infections to severe lower respiratory tract disease and can in some 
cases be fatal (Figure 1: Influenza disease burden) [22, 23]. Complications and 
severe disease are likely in young children, the elderly and the immunocompromised 
[22, 24]. 
Influenza A virus- biology and pathogenesis  
Influenza viruses belong to the family Orthomyxoviridae, a family of viruses with 
segmented negative-sense, single-stranded RNA genomes. Influenza viruses A, B 
and C cause influenza in vertebrates, including humans. IAV causes the majority of 
human influenza infections, and uniquely, possesses pandemic potential, due to its 
segmented genome, diverse host range and high mutability [25]. The IAV genome is 
comprised of 8 segments, coding for up to 16 structural and nonstructural proteins, 
and other accessory proteins expressed in a strain-specific manner [26, 27].  
 
IAV virions can range from 80-120nm sized spherical particles to almost 20 m long 
filaments (Figure 2A: Influenza A virus) [28]. The lipid membrane (host-derived) is 
studded with spikes of hemagglutinin (HA), neuraminidase (NA) and the matrix 
protein, M2. The RNA segments are wrapped in nucleoprotein (NP) and the 
polymerase, forming the viral nucleoprotein (vRNP) [27, 29]. The nomenclature of 
the virus strains is derived from the combination of H (16 subtypes) and N (9 
Figure 2. Influenza A virus: Genome organization and antigenic variability. (A) The 
influenza A and B virus particles are comprised of a ribonucleoprotein core (8 RNA 
segments associated with the RNA-dependent RNA polymerase, RdRP) in a matrix protein 
shell (M1). The lipid envelope (host-derived) displays the hemagglutinin (HA) and 
neuraminidase (NA) glycoproteins that determine host specificity. (B) Antigenic drift is a 
result of gradual accumulation of single amino acid mutations in HA or NA over time for 
immune evasion. (C) Antigenic shift is often a result of recombination of viruses from two 
different species (e.g. human and swine IAVs) in a single host, resulting in a new HA-NA 
configuration. The recombinant strain can acquire differential sialic acid specificity, 
enhancing its pathogenicity in humans. Lack of pre-existing immunity can contribute to 
greater transmission via lack of herd immunity to recombinant strains.   
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subtypes) proteins displayed on the virus surface; i.e. H1N1 or H3N2. Point 
mutations from the lack of proofreading by the RNA polymerase and selection 
pressure from host immune responses gradually lead to diversity in IAV HA and NA, 
referred to as antigenic drift (Figure 2B: Antigenic drift). The segmented nature, 
and the wide host range of IAV can lead to reassortment events between two 
different strains, in the same host cell, resulting in a new subtype, referred to as 
antigenic shift (Figure 2C: Antigenic shift). Additionally, the first exposure in life to 
influenza can imprint the immune response and prime responses during subsequent 
exposures, the phenomenon referred to as “original antigenic sin” [30-32]. 
Pandemic, and especially seasonal influenza strains vary between consecutive 
episodes/seasons necessitating annual updates to vaccine formulation [24, 33, 34].  
Transmission and replication 
IAV is spread via inhalation of aerosols and droplets containing the virus [35]. The 
virus preferentially infects respiratory epithelial cells, remaining localized to the 
airways [36]. Viremia is exceedingly rare although the absence of the virus does not 
impede systemic inflammatory effects [37]. The HA of human IAV strains recognizes 
(2,6) linked sialic acid residues on host cell glycoproteins and glycolipids[26], 
primarily in the upper respiratory tract. Avian influenza viruses are preferential to the 
(2,3) linked sialic acid residues which are present only in the lower respiratory tract, 
making humans susceptible to avian strains in the rare event of exposure [38]. The 
NA cleaves the virus free from HA-sialic acid binding, facilitating uptake via multiple 
endocytic mechanisms. The virus is trafficked to the early endosome (pH ~5) where 
HA undergoes conformational changes leading to viral envelope fusion with host cell 
membranes, releasing the vRNP into the cytoplasm where it is trafficked to the 
nucleus via nuclear localization signals on NP and host importins [39]. 
Complementary RNA is transcribed, and with that as a template, copies of new viral 
RNA are transcribed. Viral mRNA transcription is initiated with cap-snatching by 
PB2, new transcripts are synthesized and polyadenylated, and translated to viral 
proteins. New virion assembly occurs at lipid rafts and is followed by budding of 
virions [27].  
Innate immune responses to IAV 
Immune responses against IAV span the breadth of the immune system, engaging 
phagocytes, antigen presenting cells (APCs), cytokines, cytotoxic lymphocytes and 
antibody-mediated protection. IAV induces a potent innate immune response, 
required for establishment of adaptive responses; but innate responses also 
contribute to disease severity. The factors determining the delicate balance between 
pathologic and protective responses are still poorly understood. IAV, and its 
components, are sensed via pattern recognition receptors (PRR) like toll-like 
receptors (TLR- TLR7, TLR8, TLR3) [40], c-type lectin receptors (CLR-CD206, 
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CD301, DC-SIGN/CD209) [41], NOD-like receptors (NLR- NLRP3, NLRC2, NLRX1)  
and RIG-I like receptor (RLR) [42] (Figure 3: Endosomal TLR signaling). 
Recognition of IAV triggers intracellular signaling pathways which lead to cytokine 
production, and importantly, IFN-mediated antiviral signaling (MXA, ISG-15, PKR, 
IFITM etc.) [43]. The cytokines (and chemokines) recruit innate cells to the site of 
infection. 
 
 
Neutrophils are one of the first cells recruited to the nasopharynx, where they 
support macrophages in clearing apoptotic, virus-infected cells [44]. However, 
exaggerated secretion of reactive oxygen species (ROS) by neutrophils can be toxic 
[45]. Neutrophils can also perform antigen presenting functions to some extent, via 
MHC II presentation to memory CD4 T cells [46]. Neutrophils also augment the 
adaptive immune response by leaving trails of the chemokine CXCL12 for CD8+ T 
cells to the lungs [47]. Recently, however, it was shown that a subset neutrophils can 
also suppress T cell-mediated lung injury via CD11b/CD18 [48]. As important as 
neutrophil functions are during IAV infection, they are insufficient to clear infection. 
The adaptive response capable of clearing IAV infection requires professional APCs.     
In addition to neutrophils, innate lymphoid cells (ILCs) offer a potent layer of innate 
protection. Natural killer (NK) cells, now reclassified with ILC1s, are cytotoxic 
lymphocytes capable of responding to virus exposure by secreting granzymes, 
perforins, IFN and TNF , to kill infected cells and enhance the function of MNPs 
recruited to the site of virus infection [49]. NK cells are recruited to the lungs in an IL-
15-dependent manner [50], recognize IAV through natural cytotoxicity receptors and 
Figure 3. Endosomal TLR 
signaling. DCs and macrophages 
sense viruses through endosomal 
TLRs 3, 7 and 9. Monocytes 
express TLRs 4, 7 and 8. IAV, 
being a single-stranded RNA virus, 
can be recognized via TLR7. 
Double stranded RNA 
intermediates are sensed by TLR3 
and While TLR3 relies exclusively 
on TRIF and IRF3 signaling, TLRs 
7 and 9 rely on MyD88, IRF5 and 
IRF7. In PDCs, MyD88 and IRAK4 
induce transcription of IFN /  and 
subsequent interferon-stimulated 
gene signaling. 
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lyse virus-infected cells [51]. Lung resident NK cells in particular, can be primed by 
IAV to degranulate, secrete TNF, become sensitive to respiratory epithelial cells 
and also increase lung-homing capacity [52]. The killer-cell immunoglobulin-like 
receptor (KIR) repertoire of NK cells dictates their function and contributes to severity 
of IAV infection [53, 54]. The focus of this thesis, however are the MNPs and their 
individual contributions to the host response to IAV, which are discussed in greater 
detail in the next chapter. 
Human influenza disease   
Influenza infections initially present within 24-48 hours of exposure with symptoms 
like fever, muscle ache, headache, persistent cough, nasal congestion, sore throat 
and fatigue [55]. Diagnosis is confirmed by highly sensitive and rapid RT-PCR on 
nasal or nasopharyngeal samples [56, 57]. Disease management involves control of 
fever and providing symptomatic relief, and when necessary, antibiotic treatment for 
secondary bacterial infections. Severe disease follows the spread of the virus to the 
lower airways, infecting the type II pneumocytes. Diffuse alveolar damage, infiltration 
of immune cells and a “cytokine storm” mark the development of acute respiratory 
distress syndrome (ARDS) [19, 58]. Therapeutic interventions are primarily 
supportive, and aimed at managing the complications (e.g. antibiotics or oxygen 
support). Antivirals targeting the neuraminidase function of the virus (by competitive 
inhibition) like Oseltamivir are recommended within 48 hours of symptoms in risk 
groups [59]. Amantadane compounds, which inhibit the virus (only IAV) by blocking 
the M2 ion channel function, have been used previously, but are no longer 
recommended due to side-effects and emergence of drug-resistant viruses [60]. A 
cap-dependent endonuclease inhibitor drug, Baloxavir, was recently licensed for use 
in influenza [61], however, strains with reduced susceptibility to the drug are already 
being reported [62]. The most effective and promising precautionary strategy 
continues to be prophylactic annual vaccination [63].  
Global health implications of influenza 
Influenza virus has been causing pandemic infections dating as far back as 1580 
[64]. Two more pandemics followed in the 18th (1729 and 1781) and 19th (1830 and 
1898) centuries, with the 20th century witnessing 4 influenza pandemics (1918, 1957, 
1968 and 1977). Cumulatively, all the influenza pandemics may have caused fewer 
deaths than seasonal influenza in the last 100 years (Table 1: Influenza pandemics 
documented) [3, 4, 65]. The morbidity associated with influenza (disability-adjusted 
life years, healthcare costs, hospitalization, exacerbation of comorbidities etc.) incurs 
a significant burden globally [66, 67]. Of course, estimates are based on long-term 
epidemiological data and in many developing nations, surveillance data is 
unavailable, which indicates that the actual numbers may be higher than reported 
[18]. The largest contributors to disease burden in humans  are the influenza viruses 
A and B, although influenza C viruses have caused symptomatic disease and 
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hospitalizations in children under the age of 6 [68]. In turn, the largest contribution to 
influenza transmission comes from infected children with no or weak preexisting 
immunity to influenza, highlighting the need for targeted vaccination in this risk group 
[69]. Elderly individuals are also vaccinated in a directed manner but B cell 
responses are poorly adapted in this population, which can lead to incomplete 
protection [70].   
 
 
Influenza vaccines 
In the field of vaccine immunology, the development of a universal influenza vaccine 
has been compared to the holy grail [71]. Our understanding of virus evolution, 
determinants of protection, dynamics of innate and adaptive response to 
immunization and the durability of vaccine responses- all remain incompletely 
understood despite decades of tireless research on each of these aspects. Vaccine 
design has moved from crudely inactivated viruses or egg-attenuated vaccines, to 
nanoparticle based vaccines designed in a structure-guided manner (Table 2: 
Current and future influenza vaccines) [63]. Currently, three types of influenza 
vaccines are licensed for use- inactivated (whole/subunit), live attenuated and 
recombinant (HA) vaccines. Since the vaccine strains are predictively decided by the 
WHO several months before the start of the influenza season, there can be a 
mismatch between the vaccine composition and the strains in circulation. Live-
attenuated influenza vaccines (LAIV) are promising, as the cold-adapted nature of 
the strains prevents replication in the lower airways. LAIVs do not induce efficient 
seroconversion in adults, but do so in children, inducing high serum HA 
neutralization titers and mucosal IgA titers [72, 73]. LAIVs are also capable of 
inducing anti-NA titers, which have been shown to independently correlate with 
protection [74]. Moreover, LAIVs can be employed as a model system to mimic 
natural IAV infection as an alternative to human challenge models, and study 
immune responses in a controlled manner [75, 76]. 
Table 1. Influenza pandemics documented  
 
1889-1890 
1918-1920
1957-1958
1968-1969
2009-2010
Asiatic/Russian u
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Asian u
Hong Kong u
Swine u
St. Petersburg, Russia
Kansas, USA
Guizhou, China
Hong Kong SAR
Mexico
H3N8
H1N1
H2N2
H3N2
H1N1/09
0.1- 0.28%
2%
0.13%
<0.1%
0.03
1 million
20-50 million
1-1.5 million
0.75-1.0 million
18000-250000
Year Name of the 
pandemic
Location rst
identied
Virus
subtype
Case fatality 
rate
Estimated 
number of deaths
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Human challenge studies with Influenza virus 
Experimental influenza infections in carefully monitored settings have been 
performed previously with influenza virus, reviewed in [77]. Most of these studies 
were conducted to assess protective effects of immunization [78-82], to test efficacy 
of antivirals [83-85] and therapeutic monoclonal antibodies [86]. Only a handful were 
performed for understanding the pathogenesis of disease [87-89] or to better 
describe correlates of protection [74, 90-93]. More human challenge studies would 
rapidly and efficiently advance knowledge of immune function and dysfunction during 
influenza infections, but safety concerns with using wild-type, replication competent 
influenza viruses are valid, given their high and spontaneous mutability. Additionally, 
such studies would also be somewhat limited in scope by difficulty in accessing 
different compartments of the human respiratory tract. Recently, a wild-type IAV 
human challenge model (H1N1pdm09 strain) was performed safely [94]. Moving 
forward, this strategy will prove critical in addressing the global health concern of 
influenza [95].  
3.2 HANTAVIRUSES 
Hantaviruses are rodent-borne viruses transmitted to humans via inhalation of dried 
rodent excrement or saliva containing aerosolized virus. In humans, hantaviruses 
cause two distinct diseases- hantavirus pulmonary syndrome (HPS), caused by new 
world hantaviruses like Sin Nombre (North America) or Andes (Latin and South 
America); and a milder hemorrhagic fever with renal syndrome (HFRS), caused by 
old world hantaviruses Seoul (global), Hantaan (Asia), Puumala or Dobrava (Europe) 
(Figure 4: Geographical distribution of hantaviruses) [96-98]. Hantaviruses are a 
growing threat to public health with no therapeutics or licensed vaccines available. 
Table 2. Current and future influenza vaccines  
 
Recombinant 
vaccine
Split or 
subunit vacine
Whole virus
inactivated vaccine
Live-attenuated
inuenza vaccine
Vaccine type
HA (strong)
HA (strong)
NA (weak)
HA (strong)
NA (moderate)
HA (moderate)
NA (weak)
Target
+
+/–
+/–
+
Breadth of
response
Short-lived
Short-lived
Likely 
short-lived
Moderate
Durability
18-49 years of age
6-12 months of age onwards
6-12 months of age onwards
Over 2 years of age
Recommendations
Next-generation
inuenza vaccines
Antibody-based vaccines
HA stalk domain
(headless HA/chimeric HA)
HA head domain
NA head domain
M2 ectodomain
T cell-based vaccines
NP
M1
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Both HPS and HFRS are characterized by endothelial dysfunction and vascular 
leakage [99, 100]. In Northern Europe, Puumala virus (PUUV) is the primary cause 
of HFRS, although different strains circulate during different outbreaks [101]. While 
hantaviruses have likely caused HFRS for a long time, it was not until an epidemic 
illness of HFRS during the Korean war (1950-53), that the disease, named Korean 
hemorrhagic fever after the Hantaan river in Korea, became known worldwide [102]. 
The isolation of the virus in 1976 by Ho-Wang Lee and subsequent identification of a 
rodent host led to systematic analysis of hantavirus pathogenesis [103]. 
 
Puumala virus was isolated from a bank vole in Finland in 1980 [104]. The north 
American Sin Nombre virus was the first HPS-causing hantavirus isolated (1993, 
Four Corners outbreak) [105]. Compared to influenza, the field of hantavirus biology 
is still in its nascent stages. The annual disease burden of hantaviruses is 
considerably lower than that of influenza, causing 150,000 to 200,000 cases [106]. 
However, epidemics can have high case fatality rates (up to 15% for HFRS and up 
to 40% for HPS) [20]. The aerosol-based mode of transmission, virus stability, 
epidemic nature of disease and the lack of vaccines and therapeutics identify 
hantaviruses as re-emerging zoonotic pathogens of global importance. 
Hantavirus- biology and pathogenesis  
Hantaviruses belong to the family Bunyaviridae, a family of viruses with negative-
sense, single-stranded tri-segmented RNA genomes [107]. The three genome 
Figure 4. Geographical distribution of hantaviruses. Hantaviruses have a distinct 
geographical pattern, as do their reservoir hosts. HFRS-casuing “Old world” hantaviruses 
are found in Europe (Puumala or Dobrava) and Asia (Hantaan or Seoul). The disease has 
significant renal involvement. HPS-causing “New World” hantaviruses are found in the 
Americas, and include the Sin Nombre and the Andes viruses. HPS disease manifestation 
includes cardiopulmonary symptoms and epidemics with high case fatality rates have been 
reported.  
 
     New world 
Hantaviruses
Sin Nombre, Andes, 
Laguna Negra, Bayou
     Old world 
Hantaviruses
Puumala, Dobrava, 
Hantaan, Seoul
HFRSHPS
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segments named for size as small, medium and large segments, encode the 
nucleocapsid (N) protein; the glycoprotein precursor (GPC) of structural 
glycoproteins Gn and Gc; and the RNA-dependent RNA-polymerase (RdRp) 
respectively (Figure 5: Hantavirus structure). Most rodent-borne hantaviruses 
contain an overlapping reading frame in the small segment encoding the 
nonstructural protein NSs, with weak IFN-inhibitory function [108]. Hantaviruses 
were thought to have spherical shape (about 120-160nm in size) with tetrameric 
glycoprotein spikes, although recent cryo-EM analysis revealed the pleiomorphic 
nature of the virion structure [109-111]. Hantaviruses are also exceptionally stable at 
room temperature for several days, aiding their transmission to humans [112]. 
Endothelial cells are the primary target cells of hantaviruses, where they replicate 
without inducing cytopathic effects [113]. Integrins are candidate receptors for 
hantavirus attachment from data generated in in vitro models, but in vivo 
confirmation is pending [114, 115]. Recently, new world hantaviruses were shown to 
use protocadherin-1 for entry in human endothelial cells in vitro [116]. 
 
 
Immune response to hantaviruses 
Compared to IAV, hantaviruses are less well-studied and the details of the immune 
response are poorly understood. Hantaviruses are known to trigger an exaggerated 
cytotoxic lymphocyte (CTL) response [106, 117]. While CTLs are also increased in 
BAL, hantavirus infected-endothelial cells do not undergo CTL-induced apoptosis 
[99, 100, 117, 118]. CTLs accumulate in the kidneys during acute PUUV-associated 
HFRS, and the airways during fatal HPS [119, 120]. Inflammatory cytokines like 
TNFα and IL-6, secreted by innate cells like monocytes, DCs, macrophages or NK 
cells, have been reported in serum, urine and tissues of HFRS patients [121-124]. 
During hantavirus infection, NK cells rapidly proliferate and stay elevated well into 
convalescence, maintained so by IL-15 which also induced NK cell-mediated killing 
of uninfected bystander cells [125, 126]. Notably, hantaviruses have differential type 
I IFN responses, which in turn influence pathogenicity; with delayed IFN and MxA 
induction facilitating virus replication and dissemination [127, 128]. Hantaviruses can 
Figure 5. Hantavirus structure. Hantavirus particles 
are predominantly spherical in shape with some 
reports of pleiomorphic virions. The lipid envelope is 
covered in glycoprotein spikes (4 Gn and 4 Gc 
proteins per spike). The capsid contains the three 
genome segments- small, medium and large, each 
segment encapsulated by the N protein. 
Hantaviruses are quite stable compared to other 
enveloped viruses, surviving for over 10 days at room 
temperature. The prolonged survival outside a living 
host enables transmission which is typically via 
inhalation of aerosols containing the virus, and not 
via an arthropod vector like other Bunyaviruses.  
 
Gn-GC spikes
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Large
vRNA + NP 
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also induce type III IFN responses, in a type I IFN-independent manner [129]. 
Despite IFN signaling, and the ability of MxA to bind the N protein, hantaviruses still 
disseminate [130]. Unlike IAV, hantaviruses cause significant viremia and the virus 
can be detected in many tissues [131]. DCs in the airways, one of the first migratory 
cells to come into contact with the virus, have been suggested as a mechanism of 
spread [132].  
Hantavirus disease in humans 
Hantavirus manifests as two clinical diseases, HFRS and HPS, with distinct and 
shared features. Thrombocytopenia and vascular leakage are hallmarks of both 
diseases [100]. The hemorrhagic component of the diseases localizes in the 
cardiovascular system in HPS, progressively causing respiratory distress, 
pneumonia, hypotension and cardiopulmonary shock [133]. During HFRS, increased 
vascular permeability causes internal bleeding which manifests as petechiae, 
hypotension or even disseminated intravascular coagulation, and finally leading to 
kidney dysfunction [134, 135]. The incubation time for the virus can be between one 
and six weeks. The progression of HFRS is typically febrile, hypotensive, oliguric, 
polyuric and convalescent, although clinical and laboratory parameters rarely help 
identify the phase [96, 136]. Renal dysfunction in HFRS causes proteinuria and 
microscopic hematuria [137]. Pathological findings in the kidney include 
tubulointerstitial nephritis with immune cell infiltration (neutrophils, monocytes, 
macrophages, lymphocytes and plasma cells) [138]. Currently, there are no licensed 
vaccines for hantaviruses. A DNA vaccine based on the M segment of Hantaan and 
Puumala viruses, administered intramuscularly via electroporation, has 
demonstrated good seroconversion in a phase I clinical trial [139].  
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4 MONOCYTES AND DENDRITIC CELLS (DCs) 
The following section details the function of mononuclear phagocytes: macrophages, 
monocytes and DCs. In particular, the biology of the major monocyte and DC 
subsets, and their functions in the immune response to IAV and hantaviruses will be 
discussed.  
4.1 MONONUCLEAR PHAGOCYTES (MNPs) 
MNPs play important roles at mucosal barriers and serve dual purposes of protection 
and tolerance [140, 141]. MNP subsets possess varying capacity of antigen uptake, 
processing and presentation abilities and regulate adaptive responses differently 
[10]. Significant knowledge has been gained from studies on MNPs in mouse 
models, allowing for careful delineation of their ontogeny and function [142-145]. The 
ontogeny of human blood MNPs, often clouded by the great plasticity these cell 
subpopulations share, is being understood with the help of detailed studies on fate-
mapping animal models [146-148] complemented with radical studies in humans 
[149]. The distribution of these cells in human tissues, including the respiratory tract, 
is also being revealed, along with characterization of their local functions [150-160].  
 
The major MNP types have characteristic features- macrophages are excellent at 
phagocytosis; monocytes can rapidly migrate towards inflammation and produce a 
variety of inflammatory cytokines and chemokines; while DCs are excellent antigen 
presenting cells and uniquely, possess the ability to activate naïve T cells (Figure 6: 
Overview of MNP functions).  In the human immune system, two major groups of 
Figure 6. Overview of MNP functions. (A) Mononuclear phagocytes (MNPs) perform 
diverse roles as the sentinels of the immune system. MNPs can recognize pathogens via 
PRRs (TLR/NLR/RLR/CLR) and phagocytose the pathogen and debris from dead cells. 
MNPs also attract other immune cells to the site of the pathogen entry via cytokine and 
chemokine signaling. MNPs from blood can migrate to the site to kill the pathogen, 
transport the antigen to the lymph node to process and present antigens, and educate T 
and B cells. (B) The term MNP refers to three distinct cell types- monocytes (classical, 
intermediate or nonclassical), dendritic cells (CD1c+ or CD141+ myeloid and plasmacytoid), 
and macrophages (alveolar, microglia, Kupffer cells etc.). Each MNP excels at a function, 
and each monocyte/DC/macrophage subset is further specialized.  
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DCs and three distinct monocyte subsets have been identified (in blood). MNPs do 
not express any lineage markers (CD3, CD19, CD20, CD56 or CD66) but express 
high levels of HLA-DR [156, 161-163]. Comparative studies extended this knowledge 
to identify other (rarer) MNP subsets in blood, and importantly, in different tissues.  
Hematopoietic development of MNPs   
Monocytes are highly plastic cells and precise combinations of cytokines can [164] 
differentiate them into DCs and macrophages in vitro [165, 166]. In vivo, they can 
rapidly migrate to a site of inflammation and acquire a DC-like or macrophage-like 
phenotype [167-171]. Therefore, DCs and macrophages were long considered 
specialized or more differentiated variants of monocytes. Recent transcriptomics 
studies, however, have identified distinct precursors for DCs (common dendritic cell 
progenitor, CDP) and monocytes (common monocyte progenitor, CMoP). 
Macrophages can arise from embryonic precursors (yolk sac, fetal liver or bone 
marrow monocytes) early in life, and can maintain during adulthood by self-renewal 
[145-148, 159, 172-174]. DCs differentiate from CDPs under the control of FLT3 
ligand [175]. The exact developmental pathways are being constantly challenged 
and revised [147] (Figure 7: Overview of monocyte and DC hematopoiesis). 
 
Figure 7. Overview of monocyte and DC hematopoiesis. Monocytes and DCs originate 
from a common progenitor- the macrophage dendritic cell progenitor (MDP). Recent fate-
mapping studies challenged the dogma of all DCs arising from a common DC progenitor 
(CDP). The PDC lineage can be traced back to the common lymphoid progenitor (CLP). 
Also, the common monocyte progenitor (CMoP) comes directly from the MDP, 
independently of the GMP. Classical monocytes (CM) egress from the bone marrow into 
circulation, where they further sequentially differentiate into intermediate (IM) and 
nonclassical monocytes (NCM).  
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Macrophages  
Macrophages are tissue-resident professional phagocytes with antigen-presenting 
capacity. They were first described by Ilya Metchnikoff [84] in starfish larvae, when 
he observed “phagocytes” trying to surround a rose thorn used to pierce the larva. 
Since then, macrophages have been found in all tissues where they perform the 
important function of patrolling for pathogens and clear foreign bodies, pathogens, 
infected cells and debris [176]. Of all the MNPs, macrophages are the most 
terminally differentiated. Macrophages also undergo tissue-specification via 
transcriptional regulation of the core macrophage program before birth that is 
maintained by tissue microenvironment-specific cues [177]. Macrophage endo-
lysosomes efficiently process their contents, with the agenda of degrading the 
pathogen rather than preserving antigens for presentation to T cells [40, 178]. In the 
respiratory tract, alveolar macrophages (AM) are the major resident phagocyte 
population, where they are present in the lower airways, closely associated with 
alveolar epithelium [179]. Interstitial macrophages are less well-studied, as they are 
difficult to isolate from their resident tissue, the lung parenchyma [180, 181]. 
Similarly, macrophage-like cells (CD11b+CD11c+CD14+CD32+CD64+CD68+RFD-
7+) have been reported in the nasal mucosal tissue, but remain poorly studied [182]. 
In severe influenza (highly pathogenic avian strains or human pandemic strains) 
disease, AMs produce cytokinemia (IFN/ TNF, IL-1/, IL-6, and chemokines 
CCL2, CCL4, CCL5, CXCL8 and CXCL9) causing diffuse alveolar damage [183-
186]. Macrophages also form large multicellular aggregates of immune cells called 
granulomas, in chronic infections (Mycobacterium tuberculosis) [187] and 
inflammatory diseases (sarcoidosis) [188].    
Monocytes 
Monocytes in human peripheral blood are currently grouped into three major 
categories, based primarily on the surface expression of two markers, CD14 and 
CD16. Increasing expression of CD16, and decreasing expression of CCR2 on the 
surface of blood monocytes also marks the differentiation of monocytes after they 
enter circulation. At steady state, classical monocytes (CM: CD14+CD16+) are the 
most frequent subset, followed by non-classical monocytes (NCM: CD14-CD16+) 
and the transient population of intermediate monocytes (IM: CD14+CD16+) [157, 
189-191]. Following egress from the bone marrow, CMs remain in circulation for 
about a day and an estimated 99% extravasate to tissues. The remaining CMs are 
estimated to first differentiate into IMs (with a lifespan of ~4.3 days), and eventually 
into NCMs, remaining in circulation for a further 7.4 days [149]. Based on the studies 
in blood, recent studies have begun to characterize monocyte subsets in healthy 
human tissues, starting with the respiratory tract, where all three monocyte 
populations have been identified in the bronchoalveolar lavage, bronchial wash 
[151], endobronchial biopsies [150, 151], lung parenchymal tissue [153], trachea, 
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lymph nodes and pulmonary vessels [153] and compared to peripheral blood [154, 
156]. The relative distribution of these monocyte subsets is different in each of these 
compartments. While in blood, CMs are the most frequent monocyte subset, in the 
airways, often IMs are more abundant, with NCMs being detected in very low 
numbers [151].  
Functionally, monocyte subsets have distinct yet overlapping roles- CMs and IMs are 
more potent at phagocytosis than NCM. While CMs and IMs have comparable ability 
to secrete TNF, CMs are superior at IL-6 and IL-1 secretion [190]. The same 
study also showed that of the monocyte subsets, only CM were shown to present 
antigens to T cells in vitro, after first differentiating into monocyte-derived DCs. IMs, 
and to some extent NCMs, are expanded during some infections and inflammation 
[11, 176, 192, 193]. Most importantly, monocytes possess plasticity that allows them 
to rapidly differentiate into DCs and macrophages at the site of 
infection/inflammation [13, 167, 171, 190, 194, 195]. During IAV infections, monocyte 
subpopulations are also detected in the nasal mucosa [196-198]. NCMs, due to their 
rarity, have been less studied. NCMs primarily patrol the vasculature, surveil tissues 
and efficiently recognize viruses through TLR7 and TLR8 sensing, and a unique 
MYD88-MEK pathway [199-201]. 
Dendritic cells 
Dendritic cell (DC) function is essential to both the innate and adaptive arms of 
immunity. DCs are by far, the most efficient APCs, with the unique ability to activate 
naïve T cells. Canonically, DCs take up antigen at the site of infection, become 
activated, migrate to the lymph node and initiate T cell responses [10, 202]. DCs 
also efficiently cross-present antigens via MHC I, especially CD141+ MDCs [203]. 
DC ontogeny has been studied in great detail in mice with detailed functional models 
and iterative transcriptional analysis helped ascertain human counterparts of the 
mouse subsets, summarized in (Figure 8: Homology between human and mouse 
MNPs) [203-208].  
In the human immune system, DCs are grouped into two clusters: CD11c+ myeloid 
and CD123+ plasmacytoid DCs (MDCs and PDCs, respectively). MDCs can be 
further subdivided into two major subsets- CD141+ MDCs (conventional, cDC1) and 
CD1c+ MDCs (cDC2), with distinct functional advantages [159, 160, 207, 209-211]. 
The skin has a CD11c and CD1a-expressing resident population of DCs, also 
referred to as Langerhans cells (LCs). LCs were the first DCs identified and have 
been studied extensively during inflammatory skin diseases, especially psoriasis 
[212, 213]. PDCs are present in blood, but more abundant in lymphoid tissues 
including tonsils [214, 215]. PDC are potent producers of type I interferons which are 
important in protection against viruses [216-218]. 
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A slan/M-DC8-expressing subset of DCs was also identified in human tonsils, 
possessing constitutive TNFα -secreting and antigen presenting abilities, but later 
clarified to be slan+ NCMs [219, 220]. Also from tonsils, a CD207/Langerin-
expressing DC subset was identified- possibly differentiated locally from CD1c+ 
MDCs [221]. Yet another subpopulation of DCs with a distinct phenotypic signature 
was identified recently, using singe-cell RNA-sequencing, referred to as AXL and 
SIGLEC6-expressing “AS DCs” [103]. While the transcriptional studies indicate that 
these subsets of DCs are distinct, all of their (unique) functions need to be identified, 
which is often complicated by the intrinsic plasticity of DCs during inflammation and 
infection.  
Antigen presentation and adaptive immune responses 
The central topic of this thesis has been the antigen presenting cells (APCs), in 
particular, monocytes and DCs. A major function of these cells is their capacity to 
process and present antigen to T cells. However, the studies included in this thesis 
focus on the innate functions of these cells. The following paragraph provides a brief 
overview of the role of DCs in initiating adaptive immune responses. DCs can take 
up antigens via phagocytosis, pinocytosis or receptor-mediated endocytosis [222, 
223]. DCs possess specialized endo-lysosomal structures which permit optimal 
processing of protein antigens into peptides rather than rapid degradation. 
Exogenously-derived peptides are loaded onto MHC class II molecules for 
presentation to CD4 T cells [224, 225]. In contrast, endogenously expressed proteins 
Figure 8. Homology between human and mouse MNPs. Human MNPs have been less 
well-studied as compared to their murine homologs. The major monocyte and DC subsets, 
and alveolar macrophages share some markers between the species, however, making it 
easier to map human DC function based on transcriptional studies in mouse models.  
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are presented as peptides by MHC class I molecules to CD8 T cells. Peptide 
presentation via MHC I on APCs is necessary for initiating the cytotoxic effector cells 
needed to clear viral infection [226, 227].  
Additionally, some APCs can present exogenously acquired antigens on MHC I via 
the cross-presentation pathway [228], enabling APCs to present viral antigens (e.g. 
IAV) without being infected themselves. Human blood CD141+ MDCs are able to 
efficiently cross-present antigens derived from necrotic cells [203, 205]. In the 
context of viral infection, CD141+ MDCs can derive antigen from infected bystander 
cells or even CD1c+ MDCs (which are comparatively more susceptible to infection) 
[229]. In line with the overlapping nature of DC functions, the ability to cross-present 
antigens, is not restricted to the CD141+ MDCs. Human tonsil CD1c+ MDCs and 
PDCs were also shown to possess cross-presenting capacity [230]. However, recent 
high resolution studies on pure sorted human PDCs revealed antigen presentation to 
be a function of pre-PDCs (expressing CD11c, similar to MDCs) and not bona fide 
PDCs [159]. CD1c+ MDCs can also present lipid antigens via CD1a, CD1c and 
CD1d, activating αβ and  naïve T cells and NKT cells [231, 232]. Moreover, CD1c+ 
MDCs polarize the T helper cell response by secreting the optimal cytokines for 
individual Th subsets (Th1/Th2/Th17 etc.) [233].  
T cell priming and polarization by DCs is dependent on 3 signals- MHC-bound 
peptide recognition by the cognate T cell receptor (signal 1); costimulatory molecules 
(CD80/CD86) on APC signaling via CD28 (or CTLA-4) on T cells (signal 2); and 
finally, T helper cell polarizing cytokines (e.g. Th1: IL-12, IL-23, type I IFN or Th2: IL-
4, IL-5, IL-9) (signal 3) (Figure 9: T cell activation by DCs) [233, 234].  
 
 
4.2 IMPORTANCE OF TISSUE LOCATION 
In humans, blood is often the most easily accessible compartment to isolate and 
study immune cells. A majority of what is known about human MNP function is 
based on studies done on primary blood DCs or DCs differentiated from blood 
monocytes in the presence of GM-CSF and IL-4. Several DC and monocyte subsets 
have been identified in blood and their functions have been studied in great detail 
Figure 9. T cell activation by 
DCs. DCs can process 
antigens via exogenous or 
endogenous pathways. The 
processed antigen is loaded on 
MHC molecules for 
presentation to a cognate naïve 
T cell with the corresponding 
TCR. CD80/CD86 interaction 
with CD28 provides the 
secondary costimulatory signal. 
Cytokines polarize Th subsets.  
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[156, 163, 203, 235, 236]. While there are definite practical advantages to using IL-4 
and/or GM-CSF generated monocyte-derived DCs (MDDCs) and monocyte-derived 
macrophages, they are not a perfect representation of primary DCs or macrophages 
[237]. Whenever possible, obtaining primary cells from tissues of interest is 
preferable.   
Respiratory tract 
The respiratory mucosal surface has a large luminal surface area of approximately 
50-100m2 [238]. It is constantly exposed to the external environment, challenged with 
environmental factors, allergens and pathogens. The anatomical complexity in 
different compartments of the respiratory tract is reflected by their respective immune 
cell composition. Our group and others have previously showed that different 
immune cells are found in the bronchoalveolar lavage (BAL), bronchial wash (BW), 
endobronchial biopsies (EBB), lung parenchymal tissue, trachea, pulmonary vessels, 
nasal mucosa and tonsils as compared to peripheral blood in humans [151, 153, 
154, 156, 182, 197, 214]. Depending on the compartment being sampled, several of 
these DC and monocyte subsets were identified in patients with respiratory 
infections or disease, but also in healthy individuals (Figure 10: Sampling sites in 
the human respiratory tract). The invasive methods required to sample these 
locations sometimes make studies on healthy humans methodologically and ethically 
challenging. In Papers I and II, we have used easily-accessible mucosal tissues and 
well-tolerated sampling methods respectively, to overcome these challenges. 
However, as in Papers III and IV, when respiratory tissues are inaccessible, we 
must rely on blood and ex vivo techniques to perform longitudinal and mechanistic 
studies.  
 
 
 
 
Figure 10. Sampling 
sites in the human 
respiratory tract. The 
upper and lower airways 
are anatomical 
compartments with 
distinct immune cell 
composition. Routine 
tonsillectomies and 
nasopharyngeal 
aspirates allow sampling 
of the upper respiratory 
tract. Bronchoscopies 
and biopsies are used to 
sample the lower 
airways. Although the 
method is invasive, 
different branches of the 
respiratory tree can be 
concurrently sampled.   
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Lymphoid tissue 
The lymphatic system serves both circulatory and immune systems. Lymph vessels 
maintain fluid balance by restoring interstitial fluid to blood and lymph nodes act as a 
sieve trapping pathogens and foreign antigens [239]. It is also the primary site for 
antigen presentation, lymphocyte activation and proliferation, and generation of an 
antigen-specific adaptive response. In addition to lymph nodes, the bone marrow, 
thymus and spleen are considered the primary lymphoid organs. Apart from these, 
aggregate lymphoid tissue can be found governing the mucosal linings- in the 
nasopharynx as the tonsils (nasopharynx-associated lymphoid tissue, NALT), in the 
bronchi (bronchus-associated lymphoid tissue, BALT) and along the gut as Peyer’s 
patches (mucosal-associated lymphoid tissue, MALT) [240]. Of these, the NALT is of 
the most relevance during an upper respiratory tract infection like IAV [72, 241-243] 
and we have studied DCs from human tonsils as a source of DCs residing at the site 
of IAV infection in Paper I. The adenoids and the palatine tonsils form a ring of 
lymphoid tissues, creating an anatomical barrier (Waldeyer’s ring) between the 
nasopharynx and lower airways to prevent pathogen entry, and presumably, act as a 
source of immune cells [214]. 
The nasopharynx 
The human nasopharynx is the region between the nasal sinuses and the pharynx. 
The nasopharynx is covered in ciliated epithelium with goblet cells, where the sialic 
acid distribution is of the (2,3) type making it a permissive site for IAV replication 
[240, 244]. As demonstrated in a ferret model, the respiratory epithelium in the upper 
airways supports IAV adaptation in favor of increased transmissibility [242]. The 
human nasopharynx can be sampled for immune cells by nasal wash/lavage [198, 
245], biopsies [182, 246] or nasopharyngeal aspirates (as we performed in Paper II). 
The nasopharynx has been used extensively, for detection of viruses and soluble 
markers of inflammation, but few studies report cellular analysis of this compartment. 
Moving forward, the nasopharynx, especially in the context of influenza, needs to be 
better studied and utilized for its true potential- a source of longitudinal samples from 
the site of IAV replication.    
Bronchi and lungs 
The lower airways of the human respiratory tract have been investigated better than 
the upper airways, perhaps due to existence of defined sampling techniques. 
Inflammation or infection of the lower airways are a serious health condition, and 
require rapid diagnosis. The vasculature of the lung is one of the densest in the 
human body and as the organ responsible for oxygen supply, lung function is critical 
for life. Bronchoscopies for exploratory and diagnostic purposes are routinely 
performed and yield cells from the bronchi and the alveolar space, and can be used 
to collect biopsies from the bronchial walls and lymph nodes adjoining the airways 
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[150, 151, 247]. Additionally, lung parenchymal tissue can be obtained from biopsies 
as non-diseased sections are collected to compare pathology [52, 153, 156]. 
Bronchoscopies are typically not recommended or necessary during respiratory viral 
infection, but can be performed during HFRS after reduction of thrombocytopenia, as 
we performed in Paper III.  
4.3 SPECIALIZED ROLES FOR MONOCYTE AND DC SUBSETS 
DURING IAV INFECTIONS 
During IAV and RSV virus infections, monocytes and DCs have been proposed to 
mobilize from peripheral blood to the site of infection, the respiratory mucosa [196-
198]. Some of their specialized functions, in the context of IAV infection are 
discussed below. 
Alveolar macrophages: powerful MNPs  
In humans, AMs have only been investigated during severe influenza with lower 
airway involvement (pneumonia or ARDS). AMs can take up IAV by phagocytosing 
infected alveolar epithelial cells (containing intact virions) and are permissive to 
replication but produce few productive viral progeny [183, 248, 249]. When in vitro-
differentiated human AMs are exposed to IAV infection, there is a significant 
induction of interferons (IFN and IFN), cytokines (TNF, Il-6, IL-29) and 
chemokines (CCL2, CCL4, CCL5, CXCL8 and CXCL9) [184, 250, 251]. Alveolar 
damage in pandemic IAV infections (1918 and 2009) were both characterized by 
early and excessive macrophage infiltration, generally in the lungs but specifically in 
the small airways [186, 252, 253].  
Classical monocytes: migratory MNPs 
CMs are typically the first MNP to rapidly infiltrate the airways during IAV infection 
from circulation [171, 198]. CMs can phagocytose different antigens and stimulate T 
cell proliferation [191, 201]. In circulation, TNF-producing CM numbers are elevated 
(presumably, following an influx from the bone-marrow in a CCR-2 dependent 
manner) and associate with disease severity [198, 254-257]. In situ, monocytes also 
possess the capacity to differentiate into DCs, especially upon exposure to highly 
pathogenic IAV strains [171, 194]. During severe influenza, CMs are associated with 
TNF-mediated pathology in the lungs [258, 259]. As severe influenza is also marked 
by a hyper-inflammatory response, CM functions may be exaggerated. The extent of 
CM involvement in milder disease is currently unknown. Additionally, CMs, being 
susceptible to IAV infection [260, 261], experience functional impairment due to 
impaired NF-B and IFN signaling [262, 263]. A weaker IFN response may trigger a 
feedback loop, resulting in prolonged recruitment of CCR2+ monocytes to the lungs, 
contributing to tissue damage [256].  
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Intermediate monocytes: stress response MNPs   
IMs, as their name suggests, appear to be an intermediary stage between CMs and 
NCMs, and therefore, more heterogeneous than the other monocyte subsets. IMs 
are rapidly expanded in blood during viral infections like dengue [192], RSV [264] 
and chikungunya [265] or sepsis [193]. IM expansion during acute dengue infection 
was accompanied by a strong plasmablast response [192]. IMs are also potent 
producers of cytokines, especially TNF [266]. During severe IAV infection, they 
were reported to be increased in circulation and in the nasopharynx [198], but 
whether milder disease also induces the same pattern, and if the humoral response 
to IAV is influenced by the IM compartment, is unknown.  
Nonclassical monocytes: patrolling MNPs    
NCMs are estimated to remain in blood the longest (~7.4 days), of the different 
monocyte subsets [149]. NCMs also have a distinct motility pattern, whereby they 
crawl along the endothelial cells [267, 268], and can take up antigens [168, 269]. 
During homeostasis, it is believed that NCMs function as sentinels in the 
vasculature. NCMs can respond to TLR7/8 by secreting IL-6, IL-8 and CCL2 in a 
MyD88-MEK dependent manner [201]. During severe IAV infection, NCMs are 
present in the nasopharynx, and appear to correlate with local inflammation in an 
age-dependent manner [198]. Whether they are recruited from vasculature, or 
undergo differentiation in situ (from CMs recruited to the nasopharynx), and if they 
function to relieve inflammation, remains unknown.    
CD1c+ MDCs: versatile APCs   
CD1c+ MDCs (also known as cDC2s), are the most well-studied DC subset. CD1c+ 
MDCs are the most abundant DC in blood [163], have a broad TLR repertoire (TLRs 
1, 2, 4, 5 and 8) respond to a variety of pathogens, and can secrete TNF, IL-10 and 
IL-1 [270]. In vitro, CD1c+ MDCs are susceptible to IAV infection, with impairment 
of antigen-presenting functions and at higher viral loads, cell death [14, 271, 272]. 
The initiation of adaptive responses coupled with virus restriction to the tissues 
suggests APC (likely CD1c+ MDCs) are involved in transporting IAV to the draining 
lymph nodes. MDCs (CD11c+) and PDCs have been reported in increased numbers 
in the nasopharynx during IAV infection, but their functional capacity remains to be 
evaluated [196, 197].   
CD141+ MDCs: specialized APCs   
Strong CD8+ T cell responses are a hallmark of immune responses in virus 
infections, which requires presentation of antigen on MHC class I, either as a 
consequence of infection of the APC and direct presentation or via cross-
presentation, where endogenous antigen ends up on MHC I for presentation to 
CD8+ T cells. CD141+ MDCs (cDC1, expressing CLEC9A or DNGR1), are 
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specialized DCs with superior ability to cross-present antigens via MHC-I to CD8 T 
cells [203, 205, 206, 235]. They express TLR3 allowing them to respond to poly(I:C). 
CD141+ MDCs importantly, are resistant to IAV (and other enveloped virus) infection 
constitutively, due to specialized endocytic machinery and the high expression of 
Ras-related protein, RAB15 [229, 273]. CD141+ DCs are less frequent in blood than 
CD1c+ MDCs, and have never been reported in the nasopharynx before. 
Interestingly, CD141+ MDCs can also produce type III IFN, which is of special 
importance in infections where type I IFN cannot fully protect the host [152]. Whether 
CD141+ MDCs are of greater importance during IAV infection is currently unknown.  
PDCs: potent antiviral DCs   
PDCs, as described, rapidly produce large quantities of type I IFN in response to 
TLR7/9 engagement [216, 218, 274-276]. Type I IFN mediate the strongest innate 
antiviral protection by transcriptionally regulating a multitude of ISGs [250, 277]. A 
well-studied ISG, MxA (human), is expressed at high levels in PDCs [278-281]. 
Canonically, blood and tissue resident PDCs have been considered refractory to 
virus infection, largely due to their elevated, and protective, levels of MxA [229]. 
Additionally, PDCs (like CD141+ MDCs) also constitutively express RAB15 which 
restricts viral envelope fusion within the Golgi compartments, conferring these DCs 
antiviral resistance [229]. Bona fide PDCs were also shown to lack antigen-
presenting abilities [159], suggesting their principal function during IAV infection may 
be rapid and large-scale IFN production. In Paper I, we demonstrate that the 
resistance of PDCs to virus infection in vitro can be overcome by high viral load, and 
similar conditions have been shown to cause rapid apoptosis of PDCs previously 
[275, 282]. In pregnant women, a group at risk of severe influenza disease, PDCs 
were reduced in circulation and had attenuated IFN responses, contributing to lack 
of protection [283]. 
4.4 SPECIALIZED ROLES FOR MONOCYTE AND DC SUBSETS 
DURING HANTAVIRUS INFECTIONS 
Our understanding of the cellular innate immune responses to hantaviruses is 
currently very limited. More is known about the function of NK cells and CD8 T cells 
in hantavirus pathogenesis, and their contribution to vascular leakage [117-119, 
284]. A strong serological response is also seen during acute HFRS [285]. Likely, an 
innate response must precede the adaptive response. However, only a handful of 
clinical studies exist on hantaviruses where monocytes from patients have been 
studied [286-288], although other studies have been performed on patient sera to 
identify markers of disease severity [124, 285, 289-291]. During Hantaan virus 
infection, IMs were reported in increased frequencies during acute HFRS, along with 
increased expression of CD163 and CD206 on IMs [286, 288]. With Papers III and 
IV, we attempt to address this gap in the existing literature.   
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5 MATERIALS AND METHODS 
 
A brief description of the principal methods and experimental setups used in Papers 
I-IV are outlined below. Detailed information on materials and methods can be found 
in the corresponding original papers.     
 
HUMAN SAMPLE MATERIAL 
 
Ethical approval for studies involving humans and human material was granted by (i) 
the local Ethical Review Board at Karolinska Institutet, Stockholm, Sweden (Paper 
I); (ii) the Swedish Ethical Review Authority (Paper II); (iii) the regional Ethical 
Review Board at Umeå University (Paper III); and (iv) the Ethics Committee of 
Tampere University Hospital (Paper IV) respectively. Signed informed consent was 
obtained in accordance with the Declaration of Helsinki.  
 
BLOOD AND TISSUE SAMPLING 
 
Buffy coats prepared from blood of healthy volunteers were obtained at the 
Karolinska University Hospital, Stockholm (Sweden) (Papers I-III) and the Finnish 
Red Cross blood service, Helsinki (Finland) (Paper IV). Venous blood (EDTA-
containing vacutainers, BD) was also obtained from healthy volunteers at the 
Karolinska University Hospital, Stockholm (Paper II & III) and the University Hospital 
of Umeå, Umeå (CPTs, BD) (Sweden) (Paper III).  
 
Tonsils were obtained from patients undergoing routine tonsillectomies at the 
Karolinska University Hospital Huddinge and Capio Ear, Nose and Throat Clinic in 
Stockholm, Sweden (Paper I). Patients visiting the specialized Emergency 
Department and the Infectious Diseases ward at Karolinska University Hospital in 
Solna (Sweden) were sampled for blood, nasal swabs and nasopharyngeal 
aspirates (NPA) (Paper II). Matched convalescent samples were collected from 
patients who returned for repeat sampling at least 4 weeks after acute phase 
sampling.  
 
Bronchoscopies were performed on uninfected controls (UCs) and on HFRS patients 
to obtain endobronchial biopsies (EBB) and bronchoalveolar lavage (BAL) samples. 
HFRS patients were hospitalized at the University Hospital of Umeå, Umeå 
(Sweden) between 2008-2011 and underwent bronchoscopies on the earliest 
possible day during acute disease at which they could withstand the procedure and 
thrombocyte counts were higher than 100 x 109/L. Venous blood was also collected 
(CPTs, BD) from UCs and longitudinally from HFRS patients (Paper III). Venous 
blood samples (EDTA-containing vacutainers, BD) were collected longitudinally from 
   27 
HFRS patients hospitalized at the Tampere University Hospital, Tampere (Finland) 
between 2002-2007 during acute disease and convalescence (Paper IV).   
 
PROCESSING OF SAMPLES 
 
Venous blood was centrifuged at 800g/10 min/room temperature (RT) to separate 
plasma (frozen at –20°C). The cellular fraction of whole blood and buffy coats were 
reconstituted/diluted 1:1 in sterile PBS. Density gradient centrifugation was 
performed using Ficoll-Hypaque Plus (GE Healthcare) at 900g/25 min/RT (without 
brake) to obtain peripheral blood mononuclear cells (PBMCs). PBMCs were either 
used fresh or cryo-preserved in FBS + 10% DMSO at –80°C.  Tonsil tissue was 
disrupted mechanically with forceps and scissors, in R10 medium (RPMI 1640 
medium + 10% FCS + 5 mM L-glutamine + 100 U/ml penicillin and streptomycin 
each). Sequential filtration was performed through 100m and 70m nylon cell 
strainers (Saveen & Werner) to obtain a single-cell suspension. Nasal swabs (Sigma 
Virocult®) were centrifuged and frozen in RNAlater (Thermo Fisher). NPA samples 
were filtered (70m cell strainer) and centrifuged at 400g/5 min/RT. Supernatants 
were frozen at –20°C and NPA cells were washed with sterile PBS. BAL was 
obtained following 3 washes with 60mL saline solution (kept on ice), filtered through 
a 100 μm nylon filter and centrifuged at 400g/15 min/4°C to obtain BAL cells. EBB 
specimens were washed in dithiothreitol (DTT), fixed in acetone and embedded in 
glycol methacrylate (GMA) resin (Polyscience) for sectioning and 
immunohistochemistry.  
 
ISOLATION OF DCs AND MONOCYTES 
 
PDCs and CD1c+ MDCs were enriched from PBMCs and tonsil mononuclear cells 
(TMCs) using the Diamond Plasmacytoid Dendritic Cell Isolation Kit II and CD1c 
(BDCA-1)+ Dendritic Cell Isolation Kit (both Miltenyi Biotec). Enriched monocytes 
were obtained from buffy coats using the RosetteSep monocyte enrichment kit 
(StemCell Technologies). CD1c+ MDCs and CD16+ monocytes were isolated from 
enriched monocytes with CD1c+ Dendritic Cell Isolation Kit (Miltenyi Biotec) or 
CD16-conjugated microbeads (Miltenyi Biotec). MDDCs were generated also from 
enriched monocytes, by culturing them (0.5 x 106 cells per mL of R10) supplemented 
with recombinant human IL-4 (40 ng/mL) and GM-CSF (40 ng/mL) (Peprotech) for 
six days. PDCs in culture were supplemented with 1ng/mL IL-3 and CD1c+ MDCs, 
with 2ng/mL GM-CSF.   
 
ENDOTHELIAL CELL CULTURE 
 
Human primary dermal blood microvascular endothelial cells (BECs) were 
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maintained in culture in endothelial basal medium (EBM-2) and SingleQuots™ Kit 
(Lonza) and used at passages 7 to 10.  
 
IN VITRO STIMULATION AND EXPOSURE TO VIRUS  
 
In Paper I, PDCs were exposed to IAV (X-31, from Influenza A/Aichi/2/68; H3N2) in 
vitro at MOIs of 0.6 to 6.0 or CpG (ODN 2395; InvivoGen) at 1ng/mL; 3M-019 (7/8L; 
gift from Dr. R. Seder, National Institutes of Health). In Paper II, PBMCs were 
exposed to 1g/mL 3M-019 (7/8L; Invivogen) for 2h to measure TNF secretion. In 
Paper III, CD1c+ DCs and monocytes were exposed to PUUV strains Kazan or 
HTNV strain 76-118 (propagated in Vero E6 cells; ATCC) in vitro at an MOI of 0.1 to 
7.5 for 2h followed by wash, and then incubated for up to 60h. Monocytes and 
CD1c+ MDCs (40h post-infection) were adhered on Alcian blue-coated coverslips for 
immunofluorescence analysis. In Paper IV, PBMCs were exposed to 1g/mL 3M-
019 (7/8L; Invivogen) for 3h to measure cytokine production. Brefeldin A (BFA, 
Sigma-Aldrich; 10g/mL) was added after 30min. Enriched CD16+ and CD16– 
monocytes were exposed to PUUV strains Suonenjoki (propagated on MyGlaRec.B 
cells; EVAg) and Kazan (propagated on Vero E6 cells; ATCC) in vitro at an MOI of 1 
for 1h followed by wash and incubation for 20h. BECs were infected with PUUV at 
an MOI of 10 for 1hr followed by wash and incubation for 72h; or treated with 50 
ng/ml TNFα (R&D systems), for 72h. Monocytes were added to BECs at a 5:2 cell to 
cell ratio.  
  
FLOW CYTOMETRY  
 
Cells were first stained with LIVE/DEAD Fixable Dead Cell kit (Invitrogen), then 
blocked with FcR-blocking reagent (Miltenyi Biotec). Surfaced staining was 
performed with respective panels of antibodies conjugated to fluorescent dyes. Cells 
were analyzed after fixation with 1% PFA on the BD LSRII or BD LSRFortessa (BD). 
For intracellular staining to detect viral nucleoprotein (NP) or cytokines, cells were 
fixed and permeabilized using a staining buffer solution (eBioscience) and antibodies 
against IAV NP, TNF or IL-6. TNF release from PBMCs over 2h of stimulation 
with 3M-019 (7/8L) was assessed using the TNF Secretion Assay-Detection Kit 
(PE) (Miltenyi Biotec) incorporated into the surface staining protocol.  
 
MICROSCOPY  
 
GMA-embedded EBB sections (2m) were stained with respective mouse primary 
antibodies and rabbit anti-mouse biotinylated secondary antibodies. Sections were 
analyzed using a digital scanner (NanoZoomer-XR; HAMAMATSU). PUUV- exposed 
monocytes and CD1c+ MDCs were stained with human anti-PUUV serum followed 
by an anti-human IgG secondary antibody conjugated to Alexa Fluor 488. Confocal 
   29 
imaging was performed on a Zeiss LSM700 (10x objective) and visualized using FIJI 
ImageJ software (NIH).   
 
NUCELIC ACID AND PROTEIN ANALYSES  
 
Total RNA from tonsil and blood PDCs was extracted using RNeasy kit (QIAGEN) 
and cDNA was reverse-transcribed using a kit (Applied Biosystems). A 
preconfigured TaqMan low-density array (48 genes) was used to detect gene 
expression relative to housekeeping genes by qRT-PCR. Lysates of tonsil and blood 
mononuclear cells and PDCs (± exposure to IAV for 12h) were collected in RIPA 
buffer (Sigma-Aldrich) and analyzed by standard western blotting on a PVDF 
membrane. MxA expression was detected using a primary antibody (Genentech) 
and HRP-conjugated secondary antibody (Thermo Fisher Scientific).  
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6 RESULTS AND DISCUSSION 
 
As discussed in the introduction, MNPs from different anatomical compartments 
have distinctive features and different functional capabilities. Papers I and II were 
designed to identify the differences in the distribution and function of human MNPs 
from blood and the upper respiratory tract, in the context of Influenza A virus 
infection. Paper I allowed comparison of IFN responses of blood and tissue-resident 
DCs to IAV exposure in vitro. Paper I helped answer fundamental questions about 
PDC biology, their susceptibility to IAV infection and their ability to produce IFN. 
The findings in Paper I complemented the hypothesis and findings from Paper II, 
where we sought to assess MNP recruitment to the nasopharynx during ongoing 
human influenza infection with seasonal IAV strains. Paper II allowed detailed 
characterization of local and systemic MNP distribution, maturation and function, in 
conjunction with inflammation. Paper II, however, provided only a snapshot view at 
the immune system and we were also limited by nasopharyngeal cell numbers to 
perform further functional analyses. Paper III complemented Papers I and II by 
extending the course of disease with longitudinal sampling of patients, albeit in a 
different disease model, of HFRS during Puumala virus infections. Additionally, 
bronchoscopy investigations of the patients and controls augmented the findings 
observed in blood, and demonstrated the redistribution of MNPs in blood and 
airways during acute viral infection. Paper IV provided us the opportunity to assess if 
different Puumala viruses induced differential patterns of MNP redistribution during 
acute HFRS. Additionally, we were able to evaluate if circulating MNP were 
functionally impaired during the viremic phase of infection. Taken together, some of 
the results I will discuss in the following sections highlight the diverse and unique 
features of human MNP behavior during acute viral infections. The unabridged 
findings can be found in the corresponding original Papers I-IV. 
 
6.1 DIFFERENTIAL IFN RESPONSES OF HUMAN TONSIL AND 
BLOOD PDCS TO IN VITRO IAV EXPOSURE (PAPER I)  
PDCs have been considered refractory to virus infection, a feature attributed to their 
rapid and potent IFN-producing abilities [277, 292] and their constitutive expression 
of the interferon-stimulated gene (ISG), MxA [279]. In particular, PDCs have 
demonstrated resistance to IAV infection under experimental conditions, whereas 
CD1c+ MDCs are readily susceptible [14]. As PDCs are rare in circulation, and rarer 
still in non-lymphoid tissues at steady state [293], detailed comparisons between 
blood and tissue-resident human PDCs have been limited. In Paper I, we 
hypothesized that human PDCs from blood and mucosal tissues differ in 
functionality. We tested this hypothesis by obtaining PDCs from human tonsils, 
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lymphoid organs rich in PDCs [215], and resident in the upper respiratory tract- the 
initial site of IAV infection.  
We first obtained CD123+ PDCs with high purity (>95%) from both blood (buffy 
coats) and tonsils by depleting non-PDCs with microbeads. As expected, tonsils 
yielded significantly more PDCs than blood (Figure 11A) [230]. Using a custom-
designed low-density gene array, we assessed differential gene expression between 
enriched blood and tonsil PDCs. We observed no striking differences in the genes 
expressed between the PDCs from both tissues, only differences in level of 
expression. We detected comparatively higher expression of IRF7 and IFNB in tonsil 
PDCs, and higher expression of TLR7, TLR9, IRF3, MYD88, IFNAR1, IFNA1, IL-6 
and TNF in blood PDCs. Overall, we observed higher expression of IFN-signaling 
associated genes [279, 294, 295] in blood PDCs than in tonsil PDCs.  
 
To test if the steady-state antiviral resistance of PDCs could be overcome by a high 
virus dose, we exposed PDCs to increasing amounts of IAV for 12h and found viral 
Figure. 11. Human tonsil and blood PDCs are both susceptible to IAV infection in 
vitro, but tonsil PDCs display attenuated maturation and IFN  responses. (A) PDCs 
are the most abundant DC subset in the tonsils whereas in blood, CD1c+ MDCs are more 
frequent. (B) Upon exposure to increasing MOI of IAV, both tonsil and blood PDCs are 
susceptible to infection at MOI<3.0 (flow plots from representative donors). (C) At an MOI of 
6.0, tonsil (n=27) and blood (n=18) PDCs display peak median levels of IAV nucleoprotein 
intracellularly at 12-18h and 12h of in vitro exposure respectively. Blood PDCs, however, 
had comparably (D) lower median viability over time and (E) higher median expression of 
CD86 than tonsil PDCs. (F) Importantly, blood PDCs (n=12) produced at least 10-fold higher 
median IFN  at peak infection (12h) as compared to tonsil PDCs (n=9), despite similar 
pattern of IFN  induction over time.  
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nucleoprotein (NP) in both tonsil and blood PDCs at MOIs up to 6.0 (without 
complete loss of PDC viability) (Figure 11B). We studied the kinetics of viral 
replication in PDCs over 24h, quantifying the number of viral NP+ cells using flow 
cytometry. Peak NP+ PDC frequencies were observed at 12h in blood PDCs and 12-
18h in tonsil PDCs, after which we observed a decline in NP+ PDCs (Figure 11C). 
The viability of IAV-exposed PDCs continued to decrease over time as viral 
replication continued [296]. Strikingly, blood PDCs were less permissive to IAV 
replication than tonsil PDCs, and also succumbed to cytopathic effects faster 
(Figure 11D). Blood PDCs also matured more than tonsil PDCs, both in the absence 
or presence of IAV, upregulating their level of CD86 expression (Figure 11E). 
The most striking finding however, was observed in the IFN responses. Blood 
PDCs demonstrated potent secretion of IFN and significantly higher amounts than 
tonsil PDCs, with approximately 10 times higher IFN detected at 12h of IAV 
exposure (peak virus NP) (Figure 11F). Blood PDCs also expressed higher 
quantities of the ISG MxA than tonsil PDCs upon exposure to IAV. The diminished 
IFN secretion and subsequent antiviral effector expression we observed in tonsil 
PDCs may explain their higher permissiveness to viral replication than blood PDCs 
[281, 297]. Tonsil PDCs also displayed dampened IFN, IL-6 and TNF responses 
to CpG (TLR9 agonist) or 3M-019 (TLR7/8 agonist) stimulation as compared to 
blood PDCs leading us to propose that tonsil PDCs exhibit overall muted responses 
to IAV exposure or TLR agonist stimulation as compared to blood PDCs. 
The findings in Paper I, highlighted the importance of studying immune cells like 
DCs from tissues in addition to blood, as we discovered significant functional 
differences between PDCs from different tissues. In the context of IAV infection, 
where the virus initially infects the epithelium in the upper respiratory tract, replicates 
in situ, limited in vitro analysis with primary DCs obtained from blood or MDDCs 
provides a partial, and sometimes inaccurate, understanding of DC function. 
Therefore, experimental setups like in Paper I are essential for critical ex vivo 
evaluation of DC responses to IAV exposure. A limitation of the present study is that 
tonsils and blood originated from different individuals. A comparison of PDC 
responses from different tissues in the same individual would enhance the strength 
of our findings.  
It must be noted though, that locally (in the upper respiratory tract), tonsil PDCs 
could compensate for individually dampened responses by sheer excess of numbers 
due to relative abundance in the tonsils. On the other hand, perhaps the requirement 
for (and suitability of) a potent inflammatory response is lower in the upper 
respiratory tract. The location of the tonsils constantly exposes them to inhaled 
particles, antigens and pathogens compelling a muted inflammatory response in the 
tonsils [298]. Furthermore, blood PDCs, while exhibiting potent IFN responses, 
perish sooner from the cytopathic effects of IAV. Tonsil PDCs may have a small 
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survival advantage over blood PDCs resulting in prolonged IFN secretion. Due to 
the ex vivo nature of the study, we were unable to assess the contribution of DC 
mobilization to the upper respiratory tract during human IAV infection, as has been 
reported previously [196, 197]. 
6.2 RECRUITMENT OF MONOCYTES AND DCs TO THE 
NASOPHARYNX DURING HUMAN IAV INFECTION (PAPER II)  
The recruitment of monocytes and DCs to the human respiratory tract during severe 
IAV infection has been reported previously [197, 198]. However, a majority of the 
clinical studies have been performed on patients with serve influenza disease who 
require hospitalization. For example, key studies on the 2009 pandemic H1N1 IAV 
patients have been instrumental in identifying correlates of disease severity in 
pandemic influenza. Nasal CCL7, and IL-10 [198]; TNF-producing M1-like 
proinflammatory monocytes [254], plasma IL-1, IL-6, CXCL-8, IL-8, CCL2 and 
sTNFR1 [259, 299]; and suppressed Th1/Th17-related cytokines CXCL10 (IP-10), 
CXCL9 and IL-17A [300] were all reported to be predictors of severe influenza 
disease. Similar studies are required for seasonal IAV infections, which present with 
a broad range of severity- ranging from asymptomatic infection to respiratory 
disease to, in some instances, death (Figure 1). To address this void in the field, in 
Paper II, we characterized blood and nasopharyngeal MNPs in patients seeking 
healthcare with seasonal IAV infections during acute and convalescent disease. 
Investigations of nasopharyngeal monocyte and DC composition have been 
uncommon due to the physical challenges of sampling, high risk of contamination 
with cells from blood vessels and the rarity of monocytes and DCs. Some previous 
studies on nasal cells using flow cytometry were also limited technically, in the ability 
to detect multiple markers at the same time [196-198]. Using an extended flow 
cytometry panel, we were able to characterize the 3 monocyte subsets and the 3 
major DC subsets from both blood and the nasopharynx in their phenotype, 
maturation and migration marker expression.  
During 3 consecutive influenza seasons of 2016-2018, we included adult patients 
seeking healthcare with symptoms of influenza-like illness, who presented with fever 
and one or more of the following symptoms: cough, nasal congestion, headache or 
muscle ache. We excluded patients with immunodeficiencies and patients who were 
taking antibiotics, immunomodulatory or anti-inflammatory medication at the time of 
inclusion. Of the 84 patients included in the study, 40 patients were PCR+ for IAV 
infection. The IAV– patients, a heterogeneous group with symptoms of IAV infection 
but really had IBV, RSV or other viral or bacterial infections, were also assayed 
similarly but excluded from analysis. Patients were asked to return for follow-up 
sampling at least 4 weeks later, ascertained to be IAV– by PCR, to be sampled 
again. 16 healthy controls (HCs) were also included, although the broad age range 
of the IAV patients (20-98) made it difficult to find exactly age-matched healthy 
   34 
individuals. We analyzed blood and nasopharyngeal aspirates (NPA) from each 
study participant (Figure 12A). We also collected detailed patient histories and 
obtained blood chemistry results. 
 
During IAV infection, patients had cell infiltration to the nasopharynx, as compared to 
HC (Figure 12B). By flow cytometry, we were able to demonstrate that IAV patients 
have increased frequencies of lineage negative HLA-DR-expressing (LNHD) cells- 
the compartment where monocytes and DCs are typically identified- in both blood 
and in the nasopharynx (Figure 12C). In the monocyte compartment, CD14+CD16– 
CMs remained unchanged in blood, but were significantly increased in the 
nasopharynx, accounting for the bulk of the immune cell infiltration seen in this 
compartment during IAV infection (Figure 12D). Monocytes and DCs in the 
nasopharynx of patients were also more mature than their counterparts in blood, 
Figure 12. Acute seasonal IAV infection recruits monocytes and DCs to the human 
nasopharynx. We assessed immune cells in (A) blood and nasopharyngeal aspirates of 
patients using flow cytometry. (B) IAV patients (n=40) had fewer PBMCs in blood, and a 
significant cellular influx to the nasopharynx during acute IAV infection, as compared to HCs 
(n=16). (C) In both, blood and the NPA the relative frequency of lineage 
(CD3/CD19/CD20/CD56/CD66) negative HLA-DR (LNHD) cells was increased in IAV 
patients (n=22) as compared to HCs (n=12). (D) In the LNHD compartment in blood, IMs 
were significantly increased, and all the DC subsets were reduced in frequency. In the 
nasopharynx, IAV infection was accompanied by infiltration of CMs, IMs, CD1c+ MDCs, 
CD141+ MDCs and PDCs.  
 
%
  o
f L
N
H
D
 c
el
ls
D
0
20
40
60
80
HC IAV
***
HC IAV
0
10
20
30
40 **** ****
HC IAV H
C
IAV
0.0
0.5
1.0
1.5
0
2
4
6
8
10
**** ***** ******* ****
0
2
4
8
6
HC IAV H
C
IAV H
C
IAV H
C
IAV H
C
IAV H
C
IAV
Cell yield
HC IAV
0
1
2
3
4
x1
06
  P
BM
Cs
/m
L 
bl
oo
d
**
Blood
0
25
x1
06
  c
el
ls
 in
 N
PA 5
HC IAV
4
3
2
1
*
NPA
%
 L
N
H
D
 o
f l
iv
e 
CD
45
+ 
ce
lls
0
10
20
30
40
50
Blood
HC IAV HC IAV
NPA
**** ****
Lineage– HLA-DR+ cellsB C
NCM CD1c+
MDC
CD141+
MDC
PDC
NPA
Blood
A Samples analyzed
Blood
Nasopharyngeal
aspirate (NPA)
Frequencies of monocyte and DC subsets in blood and NPA
0
4
8
12
HC IAV H
C
IAV
CM IM
   35 
expressing more HLA-DR and CD86; and also in comparison to HCs. Additionally, 
CD86 expression on CMs correlated with viral load (inverse correlation with Ct 
value)- i.e., higher viral loads appeared to drive DC and monocyte maturation at the 
site of IAV infection. 
Additionally, CD14+CD16+ IMs were significantly elevated in frequency in blood and 
the nasopharynx (Figure 12D). Similar observations have been reported before, for 
other virus infections and in sepsis [192, 193]. Interestingly, in patients with the 2009 
pandemic H1N1 IAV infection, two geographically distinct cohorts reported strikingly 
increased frequencies of IMs in blood of patients [198, 254]. Only Oshansky et al. 
have previously reported increased CMs and IMs in nasal lavage of pandemic IAV 
patients. We were able to confirm that seasonal IAV infections also appear to elicit a 
similar pattern of alteration in monocyte phenotype. Additionally, we also observed 
that age was correlated positively with IMs in the nasopharynx and inversely 
correlated with IMs in blood (also reported in [198]). IMs in blood and the 
nasopharynx of IAV patients were more mature than in HCs. Blood IMs also 
upregulated CCR2 expression, and their increased frequency correlated with levels 
of plasma CCL2 (or MCP-1, monocyte chemoattractant protein 1). Previous studies 
comparing patients with seasonal or pandemic H1N1 IAV infections showed 
correlation of CCL2 with complications and pneumonia in hospitalized patients [259, 
300]. Interestingly, in our study cohort, age had an inverse correlation with IM 
frequencies in blood, and possibly with plasma CCL2. As we assayed plasma CCL2 
in only a subset of our patients, we lacked the power to test the effects of age 
directly on CCL2 levels. As a potent inducer of monocyte migration, CCL2 gradients 
in blood versus the nasopharynx can dictate severity of inflammation [301]. In murine 
models, a PPAR agonist-mediated suppression of CCL2 secretion, and therefore of 
TNF/iNOS-producing DCs was shown to ameliorate disease severity [261]. The IM-
CCR2-CCL2-TNF axis may be crucial to reducing influenza severity and merits 
further investigation.  
We detected the 3 major DC subsets- CD141+ MDCs (cDC1), CD1c+ MDCs (cDC2) 
and PDCs in blood; and in a subset of HCs also in the nasopharynx. Often, NPA 
samples from HCs yielded few to no DCs, as we expected. In IAV patients, all 3 DC 
subsets were found in strikingly reduced frequencies in blood, and in comparably 
increased frequencies in the nasopharynx in IAV patients (similar to previous reports 
in pediatric RSV and IAV infections [196, 197]). We also observed an inverse 
correlation between age and the frequency of CD1c+ MDCs- in contrast to the 
positive correlation seen with IM frequencies. Nasopharyngeal DCs in the patients 
were also more mature as compared to DCs in blood, with MDC maturation 
correlating with CM maturation (which in turn correlated with viral load).  
The lowest CM frequencies were observed in blood at day 1 but in the nasopharynx, 
peak CM frequencies were seen later (day 3) than in blood. Overall, CM frequencies 
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were seen to fluctuate over disease course, leading us to speculate if CMs were 
being replenished from the bone marrow as has been postulated before [149]. CMs 
could either be recruited to the nasopharynx, or be differentiating into IMs in 
circulation, or as we suspect- both. Peak IM frequencies were also found earlier in 
blood (day 1) than in the nasopharynx (day 3-4) during IAV infection. In the 
nasopharynx, peak frequencies of the different DC subsets were observed at 
different days of symptoms, suggesting differential kinetics of their recruitment to, or 
differentiation in, the nasopharynx. It is currently unclear if in addition to CMs, IMs 
and DCs are also actively recruited to the nasopharynx, or the cells we identified 
there were a consequence of local differentiation from CMs. In a human 
experimental endotoxemia model, LPS injection induced loss of all 3 monocyte 
subsets from circulation within 2 hours [149]. Whether IAV infection is sufficient to 
induce similar recruitment of all monocytes (and DCs) to the nasopharynx, remains 
to be tested with human experimental challenge models with IAV [74, 94], or using 
the live-attenuated influenza vaccine (LAIV) to mimic a human infection model.  
We also observed increased levels of the cytokines TNF (Figure 13A), IL-6 and 
IFN in both plasma and the nasopharynx. In both compartments, cytokine levels 
correlated with CM frequencies. Supporting this, we found that it was older patients, 
who had more CMs in blood than IMs, that had higher plasma TNF levels. Since 
TNF was elevated locally and systemically during IAV infection, we sought to 
identify its cellular source. Due to limited cell yields from the nasopharynx, we had to 
limit our functional studies on the MNPs from blood in patients and HCs. We used a 
TNF-secretion assay which immobilizes any TNF released by a cell on the 
surface of the same cell, enabling simultaneous detection of the cytokine secreted 
and the phenotype of the cell via flow cytometry (Figure 13B). In IAV patients, 
unstimulated monocytes and DCs release TNF (mostly from CMs and IMs) as 
compared to cells in HCs (Figure 13C). Upon further stimulation with a TLR7/8 
agonist, all monocyte and DC subsets in patients and HCs produce TNF, with 
stimulated cells from patients often exceeding the levels seen in HCs. Therefore, 
monocytes and DCs in blood actively contribute to systemic inflammation in a TNF-
mediated manner. In line with previous reports of TNF-expressing monocytes 
contributing to severe disease independent of comorbidities [254], we showed that 
CMs and IMs contribute to seasonal influenza disease. Mature CMs, IMs and DCs 
are all present in the nasopharynx during infection in the same individuals. And we 
observe a correlation between plasma and nasal TNF. We can extrapolate from 
our findings to propose that monocytes and DCs recruited to the site of infection, the 
human nasopharynx, contribute to TNF-dependent local inflammation.  
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Lastly, we sampled IAV patients during convalescence, to assess if the changes we 
observed in MNPs were normalized to reflect levels seen in HCs. Indeed, the 
frequencies of CD1c+ MDCs were increased in blood and reduced in the 
nasopharynx; and IMs were reduced in both compartments. With Paper II, we have 
shown that a broader understanding of underlying immune processes can be 
obtained by sampling the respiratory tract during infection in a less invasive manner. 
We also demonstrate, once again, the importance of studying MNPs at the site of 
infection in addition to MNPs from blood.  
6.3 REDISTRIBUTION OF MONOCYTES AND DCs IN PERIPHERAL 
BLOOD AND AIRWAYS OF ACUTE PUUV-HFRS PATIENTS 
(PAPER III)  
Hantaviruses are transmitted via inhalation similar to influenza viruses, but are quite 
different in their pathogenesis. In Sweden, the endemic strain of hantavirus, 
Puumala virus, causes hemorrhagic fever with renal syndrome (HFRS). The target of 
the virus is the vascular endothelium, which supports replication without the 
manifestation of cytopathic effects. HFRS is accompanied by exaggerated immune 
responses, typically mediated by NK cells and CD8 T cells. Monocytes and DCs in 
particular, may contribute to both orchestration of the adaptive responses, and also 
to the inflammation seen in HFRS, both of which contribute to vascular leakage. The 
in situ immunological events following the initial entry of the virus via the airways, 
and replication in vasculature of the airways are poorly understood. Although HFRS 
primarily causes renal dysfunction, increasingly, respiratory distress has been 
reported in these patients [122, 284] as hantaviruses replicate in the lower airways. 
However, the thrombocytopenia associated with acute HFRS and the risk of 
Figure 13. During IAV infection, monocytes produce TNF . (A) IAV infection (n=31) is 
marked by high levels of TNFα in circulation (IAV: n=31) and locally, in the nasopharynx 
(IAV: n=18), as compared to HCs (n=12). (B) We measured spontaneous and TLR agonist-
stimulated TNFα  production by MNPs in circulation, using an in vitro TNFα secretion assay. 
(C) In IAV patients (n=9), all monocytes and DCs spontaneously secreted TNFα during 
acute infection, as compared to HCs (n=5). CMs and IMs produced the highest amount of 
TNFα among the MNPs. 
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aerosolizing cell-free virus restrict airway sampling in general and dismiss 
longitudinal sampling of the airways. Despite this limitation, in Paper III, we 
performed bronchoscopies (biopsies and lavage) on 17 patients with acute HFRS 
due to Puumala virus infection (as early as possible) and 12 age-matched uninfected 
controls (UCs); and obtained peripheral blood samples (Figure 14A). 
 
 
Immunohistochemistry revealed significant infiltration of CD8+ T cells and HLA-DR+ 
cells into the airways of patients during acute HFRS as compared to UCs, and was 
confirmed by flow cytometry on BAL. CD8+ T cell infiltration to bronchial tissues in 
Figure 14. Acute HFRS causes redistribution of monocytes and DCs. (A) We obtained 
blood samples during acute (n=28) and convalescent (n=30) HFRS from 17 patients and 12 
uninfected controls (UCs). Bronchoscopies were performed on all patients during acute 
disease and on 16 UCs. (B) During acute HFRS, peripheral blood frequencies of all 
monocyte and DC subsets were severely reduced and normalized to levels seen in UCs 
during convalescence. (C) IMs, NCMs and CD1c+ MDCs upregulated CCR7 in acute 
HFRS, suggesting migratory behavior. (D) When exposed to PUUV in vitro, CMs (n=4) and 
CD1c+ MDCs (n=6) also upregulated CCR7 (flow plots from representative donors). 
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HFRS associated with CD123+ cell infiltration. However, the effects of HFRS are 
largely systemic and viremia during HFRS was consistently present in blood over 
BAL. Therefore, we characterized monocytes and DCs in blood using flow 
cytometry, in an attempt to understand the MNP responses to the virus and/or 
inflammatory cytokines in circulation; and how MNPs may contribute to CD8+ T cell 
infiltration and activation. 
During acute HFRS, CMs, IMs and NCMs were all reduced in numbers in 
circulation, as compared to UCs (Figure 14B). During convalescence, when viremia 
was reduced, the numbers of monocytes returned to steady-state levels. Similarly, 
numbers of CD1c+ MDCs, CD141+ MDCs and PDCs were all strikingly reduced in 
circulation during viremic HFRS and normalized during convalescence. We next 
examined for evidence of monocyte and DC migration to peripheral tissues [302, 
303] or to the lymph nodes [304] by assessing CCR7 expression. Notably, the IMs, 
NCMs, CD1c+ MDCs and PDCs remaining in blood during acute disease all 
displayed increased CCR7 expression as compared to UCs or during convalescence 
(Figure 14C). Taken together, we found that acute HFRS was characterized by a 
marked depletion of monocytes and DCs, and cells remaining in blood, were both 
mature, and showed indications of migratory signaling. 
Additionally, we also performed in vitro experiments where we exposed CMs and 
CD1c+ MDCs to PUUV. PUUV did not induce any cytopathic effects in the cells, but 
induced changes in chemokine receptor expression (Figure 14D). This observation 
supports our idea that loss of MNPs during viremic infection may be due to migration 
as opposed to death. We also noted that CCR2 expression was reduced but CCR4, 
CCR6 and especially CCR7 expression, were all increased on CMs and CD1c+ 
MDCs, suggesting the CCR7 expression we observed on MNPs in patients is a 
possible consequence of PUUV exposure. 
If MNPs indeed migrate to the airways during HFRS, their presence may explain the 
increased CD8+ T cells in the airways and increased respiratory symptoms seen in 
HFRS [118, 122, 284]. Further investigations are required to understand the 
dynamics of MNP redistribution and activation during HFRS and their individual 
contributions to inflammation.    
6.4 PRONOUNCED DEPLETION OF NONCLASSICAL MONOCYTES 
DURING SEVERE PUUMALA VIRUS HFRS (PAPER IV)  
To expand on our findings in Paper III, in Paper IV, we enquired if different Puumala 
virus strains associated with somewhat different clinical phenotypes, elicit distinct 
patterns of MNP mobilization and/or redistribution. We also sought to assess the 
effects of viremia in HFRS on the functions of MNPs. Lastly we tried to identify innate 
immune determinants of HFRS severity.  
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We studied a cohort of 23 HFRS patients from Tampere, Finland who presented with 
renal symptoms (unlike the Swedish cohort in Paper III). We obtained acute and 
convalescent phase peripheral blood samples from all patients and 9 UCs. Acute 
disease in patients was marked by thrombocytopenia, and elevated CRP and 
creatinine, which subsided during convalescence. We also calculated an adapted 
severity score (a-SOFA; based on thrombocyte counts, creatinine levels and mean 
arterial pressure readings) and stratified patients into low (a-SOFA<5) or high (a-
SOFA≥5) severity groups. Patients with higher severity also had higher total 
leukocytes during acute HFRS.  
Monocyte subsets were identified using flow cytometry, and the most striking 
observation involved the NCMs, which were significantly depleted during acute 
disease as compared to UCs (Figure 15A). Patients with severe disease were 
particularly depleted of NCMs during acute disease, and the NCM frequencies 
remained below median levels seen in UCs even during late convalescence (day 
360) (Figure 15B). Meanwhile CMs (n.s.) and IMs (significant) were elevated during 
acute disease, indicating restructuring of the monocyte compartment during acute 
HFRS. No major changes were observed in the DC compartment. Overall, the 
pattern of monocyte distribution in this cohort was different from what we observed in 
Paper III. The variation we report may be attributed to the different virus strains in 
circulation in Northern Sweden and Eastern Finland [101, 305] as patients in the 
current cohort exhibited no obvious pulmonary complications. Detailed phylogenetic 
analysis of the two viruses would provide clarification. An alternative hypothesis is 
that the current cohort does include samples from patients prior to 5 days with 
symptoms. And lastly, in both instances, the days with symptoms are self-reported 
by the patients and may introduce additional variation by altering the physiological 
window being analyzed. The viral loads in both cohorts, although, were comparable 
(~104 to 106 viral copies/mL of plasma). 
Acute HFRS was also marked by IMs and NCMs upregulating surface expression of 
HLA-DR, CCR2, and CCR7, as compared to UCs, which normalized during 
convalescence. CCR2 expression on IMs was particularly elevated in patients with 
severe disease who we suspected may have higher systemic inflammation 
(behaving similar to the IMs from IAV+ patients in Paper II). However, cytokine 
responses were not comparable between both groups of patients, with only mildly 
elevated plasma cytokine levels seen in the HFRS cohort. Elevated cytokine levels 
in plasma, though, correlated well with elevated creatinine levels and 
thrombocytopenia. 
Similar to our observations in Paper III, all monocyte subsets had increased CCR7 
expression during acute HFRS, suggestive of signaling towards peripheral migration. 
Strikingly, the patients with less severe disease had higher CCR7 expression on IMs 
and NCMs than patients with severe disease (Figure 15C). Efficient CCR7 signaling 
Figure 15. Severe HFRS is accompanied by a distinct loss of nonclassical monocytes 
and impaired TNFα secretion. (A) During acute HFRS, NCMs were severely depleted in 
blood as compared to an uninfected control (UC), reappearing during convalescence (flow 
plots from representative donors). (B) Patients with severe HFRS (higher a-SOFA score) 
displayed dramatically low NCM frequencies during acute disease; with peak CM and IM 
frequencies observed later than in patients with lower a-SOFA scores. (C) IMs and NCMs in 
patients with severe disease upregulated CCR7 to a lower extent suggestive of delayed 
recruitment of CMs and IMs to the periphery during severe disease. (D) CD11c+ myeloid 
cells during acute HFRS were impaired in their ability to respond to TLR7/8 agonist 
stimulation and secrete TNFα as compared to UCs. (E) The extent of impairment of TNF  
response correlated with level of thrombocytopenia (in patients with severe disease).   
 
α
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may induce sufficient recruitment of monocytes to the lymph nodes in these patients, 
reducing severity of their disease. 
 
Conversely, severe disease may be aided by weaker recruitment of monocytes. This 
hypothesis also supports our observation of peak CM and IM frequencies later in 
severe patients as compared to patients with less severe disease (Figure 15B). The 
myeloid cell compartment (composed primarily of monocyte subsets) in HFRS 
patients was impaired in its ability to respond to further TLR stimulation (quantified in 
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terms of TNF secretion) in the earliest period of acute HFRS, suggestive of 
exhaustion in this compartment (Figure 15D). Patients with the lowest thrombocyte 
counts (and severe disease) were also most impaired in TNF release (Figure 15E). 
Assaying the responses of blood, however, only offers incomplete knowledge of 
inflammatory processes as we and others have demonstrated. Therefore, further 
testing is required to identify the fate of the monocytes after (likely) exposure to virus, 
and address their exact contribution to HFRS. For example, acute kidney injury and 
renal dysfunction are hallmarks of HFRS but are typically assessed indirectly [138]. 
A recent study showed correlation between excreted IL-6 (in urine) and proteinuria in 
HFRS, suggesting local proinflammatory cytokine production- perhaps by monocytes 
or macrophages recruited to the kidneys [137]. So, the patients with severe 
thrombocytopenia, and impaired TNF peripheral blood responses, may in fact have 
cytokinemia in the kidneys, if monocytes were present in increased numbers in the 
kidneys during acute HFRS. 
During acute HFRS, IMs retained within vasculature, likely differentiate into NCMs 
[149], replenishing the depleted NCM pool. The CD16+ monocytes (IMs and NCMs), 
in addition to CCR2 and CCR7, also upregulated their expression of the endothelial 
adhesion marker CD62L (or L-selectin), which helps leukocytes tether and “roll over” 
endothelial cells. The underlying reason for, and the ultimate fate of the seemingly 
depleted NCMs is currently unknown. In vitro, we tested if CD16+ monocytes (IMs + 
NCMs) and CD16– monocytes (CMs) demonstrate differential adhesion and 
migration behavior upon exposure to cell-free hantavirus or hantavirus-infected 
endothelial cells. Recapitulating the responses seen in patients, ex vivo CD16+ and 
not CD16–monocytes upregulated CD62L expression. CCR7 expression was only 
mildly elevated, and only when cells were exposed to virus-infected endothelial cells. 
Preliminary results suggest that CCR7 upregulation may require both cell-free and 
endothelial cell-associated virus (as in human infection), and additional TLR 
signaling or soluble factors. 
Typically patrolling the vasculature, NCMs are retained in capillaries for ~9 minutes 
at steady-state [149, 268]. In murine models, NCMs respond to inflammation in the 
endothelium by recruiting neutrophils to kidneys in a TLR7-dependent manner. The 
neutrophils proceed to cause endothelial cell necrosis and the monocytes remove 
cellular debris [201, 268, 269]. While this mechanism has not been investigated in 
humans, it is likely that NCMs behave similarly, offering an explanation correlating 
the loss of NCMs and the renal dysfunction in HFRS. Perhaps, in patients with 
severe disease, more NCMs are lost from circulation due to increased retention in 
the renal capillaries. Whether NCMs support or mitigate inflammation and 
subsequent vascular leakage during HFRS, remains to be understood with further 
investigation. 
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7 CONCLUSIONS 
 
The constituent studies of this thesis were aimed at understanding how monocyte 
and DC distribution and function vary during human influenza A virus (IAV) and 
hantavirus infections in order to decipher their role in viral pathogenesis. Monocytes 
and DCs are critical orchestrators of the innate immune response to virus infection. 
In vitro studies and animal models have significantly improved our understanding of 
their ontogeny, biology and function, both at steady state and in disease models. 
Still, aspects of their function remain unknown, especially in the context of human 
disease. Furthermore, the anatomical dependency of MNP function requires 
comparative investigations of MNPs in blood and tissues, also in humans. With 
viruses of global health significance, the shortage of effective therapeutic 
interventions urges us to find alternative strategies to treat disease. Modulating the 
immune response to fight infections, especially in diseases with immune-mediated 
mechanisms of pathogenesis, require extensive knowledge and understanding of 
the host immune response. Characterizing the dynamics of innate responses to IAV 
and hantavirus infections, and searching for markers of disease severity will help 
uncover new targets for intervention. Once achieved, the discoveries made in a lab 
must be translated to the clinic and can eventually contribute to protecting human 
health.    
 
In summary, the major findings from this thesis are as follows: 
 
• Human DCs from distinct anatomical locations have different abilities to 
mediate antiviral protection (Paper I). 
 
• During acute influenza infection, monocytes and DCs are recruited to the 
nasopharynx where they can promote inflammation (Paper II).   
 
• During acute HFRS, circulating monocytes and DCs are activated and 
migrate from blood to the peripheral tissues and/or lymph nodes (Paper III).  
 
 
• Severe HFRS causes pronounced loss of patrolling monocytes from 
peripheral circulation, as monocytes may be held within the blood vessels of 
the kidneys (Paper IV).   
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8 FUTURE DIRECTIONS 
The findings in the current thesis have increased our understanding of monocytes 
and DCs, but also exposed many remaining questions that can be explored with 
future studies.  
In Paper I, we established a novel system to study PDCs from the site of IAV 
infection and compare their responses to blood PDCs ex vivo. Human tonsillar tissue 
supports explant cultures and have been previously used to model HIV infection in 
mucosal tissues [306-308]. Tonsil explants can be used to study how IAV infection 
influences PDC behavior within the tissue architecture. We can assess if PDCs 
egress from the tonsils to the nasopharyngeal epithelium in response to IAV 
infection. Whether the attenuated IFN responses are still protective to surrounding 
cells, or if tonsil PDCs promote recruitment of blood PDCs to the site of infection. 
Unlike ex vivo suspension cultures, explant systems support extended experimental 
periods, enabling us to map the kinetics of in situ PDC responses to IAV.   
In Paper II, we capitalized on clinical collaborations, our existing expertise in flow 
cytometry and unique sampling methods, to assess cellularity in a relevant 
anatomical compartment- the nasopharynx. Moving forward, over the upcoming 
influenza seasons, this study design can be used to precisely track immune cells 
with greater complexity over time and perform functional studies on nasopharyngeal 
cells. Adaptive immune cell recruitment can be assessed. Extrapolating from studies 
on NK cells from this patient cohort [52], hyperresponsiveness or functional 
impairment of nasopharyngeal monocytes and DCs can be investigated. In situ 
differentiation of monocytes into DCs or macrophages can be studied. The virus can 
be typed using next generation sequencing methods to identify drift variants within a 
single patient, a single season, and between seasons.  
On the clinical aspect of this study, an innate immune profile can be created 
predicting progression vs resolution of disease. This should include a severity 
scoring system for seasonal influenza, to help stratify the patients on virological, 
immunological and clinical findings. By recruiting household contacts of patients 
[198], or individuals being vaccinated with the LAIV [72, 73, 76, 78], it would be 
possible to study early immune responses in asymptomatic individuals exposed to 
IAV, and track them over time. The study setup can be scaled up to multi-centric, 
longitudinal studies spanning the entire influenza pyramid and season. Studies like 
these would help prepare logistically for research studies when the next influenza 
pandemic hits.  
In Paper IV, we were able to extend the scope of Paper III. With further in vitro 
experiments, we can try to address the fate of the different (sorted) monocyte and 
DC subsets after (likely) exposure to virus, and address their exact contribution to 
HFRS. Assaying the responses in blood, however, only offers incomplete knowledge 
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of inflammatory processes as we and others have demonstrated. Performing renal 
biopsies on patients is only recommended in extremely atypical cases for differential 
diagnosis. However, urine samples from patients can be analyzed for leukocytes and 
soluble markers of inflammation. There is a possibility to obtain archived renal biopsy 
samples from HFRS patients. Using immunohistochemistry and imaging methods, 
we can study if NCMs adhere to the endothelium in renal vasculature and 
extravasate into glomerular tissue during hantavirus infection. We can explore for 
NCM sequestration in the kidneys during HFRS, as seen before in animal models 
[201, 268]. With TranswellTM systems, we can also assess the individual contribution 
of different sorted monocyte subsets to the endothelial dysfunction and vascular 
leakage seen in HFRS.   
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